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  The continued propagation of antibiotic resistance requires the development of 
new  therapeutics.  The  lipopeptide  antibiotic  enduracidin  has  demonstrated  high 
activity  against  Gram-positive  pathogens  including  methicillin-resistant 
Staphylococcus aureus. In addition to a lack of cross-resistance with existing antibiotic 
classes,  enduracidin  has  no  known  transferrable  resistance  mechanism.  The 
development of enduracidin as a human therapeutic is hampered by its poor solubility 
in  plasma. Utilizing  chemical  and genetic  techniques,  analogs of enduracidin have 
been  produced  and  evaluated  for  biological  activity.  Making  use  of  the 
hydroxyphenylglycine  (Hpg)  biosynthetic  pathway,  fluorine  was  incorporated  into 
enduracidin with minimal to no loss of bioactivity. 
 T h e   s e m i s y n t h e t i c   c h e m i c a l   m o d i f i c a t i o n   o f   e n d u r a c i d i n   p r o v e d   t o   b e  
challenging.  The  chemical  nitration  of  the  Hpg  residues  was  unsuccessful. 
Modifications to the lipid tail by cleavage at the C2-olefin with ozone and the use of 
Diels-Alder  reagents  to  react  with  the  lipid  tail  diene  also  proved  unsuccessful. 
However, the reduction and dihydroxylation modifications of the lipid tail diene were 
successful.  Introduction  of  polar  hydroxyl  groups  onto  the  alkyl  tail  reduced 
bioactivity while reduction of the diene had no significant effect. 
  Analysis of the biosynthetic pathways involved in producing the lipid tail and the unusual amino  acid  enduracididine  yielded some  insights into the  formation of the 
antibiotic. Through complementation of mutants having disruptions in the biosynthetic 
gene  cluster  and  crystallographic  data,  the  function  of  EndR  as  a  cyclase  was 
established.  Additionally,  the  use  of  4-hydroxyarginine  as  an  intermediate  in 
enduracididine biosynthesis was demonstrated. The ability of EndQ to function as a 
transaminase  on  both  4-hydroxyarginine  and  2-ketoenduracididine  was  also 
established. The specific functions of EndP and EndQ have not been determined. The 
introduction of the lipid tail diene by the three enzymes Orf39, Orf44 and Orf45 was 
confirmed. Orf45 functions as a CoA ligase and a dehydrogenase to introduce the C2 
double bond. The functions of Orf39 and Orf44 appear to be the introduction of the C4 
double bond and isomerization of the C2 olefin. © Copyright by Neal C. Goebel
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INTRODUCTION
Neal GoebelHistory of Antibiotics
  The discoveries of Koch and Henle linking infectious disease to bacteria allowed 
for  the  modern  development  of  antibiotics.1  Research  toward  combating  these 
pathogenic  bacteria  developed  along  two  routes  during  the  first  half  of  the  20th 
century. The discovery of penicillin by Alexander Flemming in 1928 and its eventual 
purification and therapeutic development 12 years later by Florey et al. was the first 
example of an antibiotic discovered from natural sources.2 Penicillin is a beta-lactam 
antibiotic  produced  by  the  fungus  Penicillium  rubrum  and  inhibits  cell  wall 
biosynthesis  by covalently binding  to  the  transpeptidase,  carboxypeptidase  and/or 
endopeptidase  enzymes (Fig. 1.1A).3 The  development of penicillin as a  drug  was 
spurred by the treatment of infections by the military during World War Two. During 
the first five months of 1943 400 million units of penicillin were produced. Two years 
later, in August 1945, advancements in technology led to the production of 650 billion 
units of penicillin monthly.4 An alternate approach to the development of antibacterial 
therapeutics was ongoing during the development of penicillin.
  The  discovery of  Prontosil,  the  first  of  the  ‘sulfa’  drugs,  resulted  from  the 
intensive synthetic chemistry program run by Bayer.5 The compounds were found to 
be active against both  Gram-negative  and Gram-positive infections. The lack of in 
vitro activity by Prontosil led to the discovery that the compound served as a prodrug 
and  was  activated  by  reduction  of  the  diazene  linkage  releasing  the  bioactive 
sulfanilamide  (Fig.  1.1B).6  Sulfanilamide,  developed  24  years  prior  by  the  dye 
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Figure 1.1 A) Structure of penicillin G. B) Structures of Prontosil and sulfanilamide produced 
by reduction of the diazene bond.
A Bindustry, was not protected under patent allowing  for the rapid spread of sulfa drug 
production. Within a year of publication in 1935 the sulfonamides became the first 
medically used  antibiotics.7  The  sulfa  drugs,  p-aminobenzoic  acid  analogs,  act  as 
competitive inhibitors of dihydropteroate synthase during folate biosynthesis (Fig 1.2). 
The capability of producing kilotons of compound via synthesis led to the dominance 
of the sulfa drugs in clinical use until the mid 1950s. The sulfa drugs established that 
synthetic chemistry can yield new antibiotics.
  The  development of  natural  products chemistry in antibiotic  research quickly 
gained  dominance.  Through  the  50s  and  60s  pharmaceutical  companies  invested 
heavily on the acquisition and screening of bacterial strains for antibiotic production. 
The actinobacteria, specifically the genus Streptomyces, were found to be prodigious 
producers of bioactive compounds. The era became the golden age of antibiotics. In 
the  1970s  the  pace  of  drug  discovery began  to  slow.  New  chemical  classes  of 
compounds began  to  be  harder  to  find.  Unique  mechanisms of  action  were  more 
difficult to  discover.  The  discovery rate  for  antibiotics  began  to  slow  immensely. 
Natural product sources were no longer providing  high returns for the discovery of 
new compounds. Efforts were focused on the semisynthetic modification of existing 
compounds  through  medicinal  chemistry in  an  effort  to  overcome  resistance  and 
increase efficacy.8 During the past 15 years the exploration of combinatorial chemistry 
in target-directed drug discovery has yielded little success in providing new chemical 
scaffolds. The lack of profit margin in antibiotics coupled with the increasing cost and 
difficulty of FDA approval has decreased pharmaceutical industry interest in antibiotic 
discovery. The lack of funding  in academic natural products chemistry research has 
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Figure 1.2 Biosynthesis of dihydropteroate by dihydropteroate synthase.slowed the discovery of new chemical entities for use as antibiotics even further. It 
appears increased profits or  an  increase  in  the  infectious disease  mortality rate  is 
needed to spur the funding of antibiotic discovery.
Primary Antibiotic Modes of Action
  Antibiotics can be  classified  into  five  general  modes of action:  Inhibition of 
DNA functions;  disruption  of  protein  biosynthesis;  interruption  of  vital  metabolic 
pathways; disruption of cell membrane function; and blocking  cell wall biosynthesis. 
Each mode  has its own  benefits and  weaknesses. Different classes of  bacteria  are 
susceptible to certain antibiotics, i.e. glycopeptides are effective against Gram-positive 
bacteria  while  inherently  inactive  against  Gram-negative  bacteria  due  to  the 
lipopolysaccharide (LPS) outer membrane.
 T h e   i n h i b i t i o n   o f   D N A   r e p l i c a t i o n / t r a n s c r i p t i o n   i s   d e m o n s t r a t e d   b y   t h e  
quinolones. The fluoroquinoline ciprofloxacin, for example, binds to DNA gyrase and 
topoisomerase  blocking  DNA  replication  and  causing  fracturing  of  the  DNA.9 
Rifampin, a strong inhibitor of RNA polymerase, blocks transcription and ultimately 
prevents  protein  biosynthesis.10  Antibiotics  targeting  DNA  regulatory proteins  are 
effective due to the structural differences between bacterial and mammalian proteins.  
  Inhibition of the bacterial ribosome is effective due to the significant differences 
from the mammalian ribosome. The translation of RNA to a protein is performed by 
the ribosome, having 30S and 50S portion in bacteria. Drugs such as chloramphenicol 
and  erythromycin  block  protein  synthesis  by binding  the  the  50S  portion  of  the 
ribosome. Phenicol antibiotics prevent peptide bond formation while macrolides block 
translocation of the ribsome along  the RNA strand. The aminoglycosides bind to the 
ribosome complex in several areas causing misreading and early termination of protein 
synthesis.11 The  tetracyclines  block  tRNA from  binding  to  the  30S  portion of  the 
ribosome.12  The  stalling  of  protein  synthesis  leads  to  bacteriostasis  necessitating 
4immune  response  for  elimination  of  bacterial  infection.  The  misreading  of  RNA 
caused by some aminoglycosides is bactericidal.
  The direct inhibition of vital metabolic pathways unique to bacteria is the last 
mode  of  intracellular  antibiotic  action.  The  sulfonamides  and  trimethoprim  both 
inhibit  the  biosynthesis  of  tetrahydrofolate,  a  vital  cofactor  in  metabolism. 
Sulfonamides, as mentioned earlier,  inhibit dihydropteroate synthase. Trimethoprim 
inhibits  dihydrofolate  reductase.13  The  two classes of  drugs act synergystically by 
competitively inhibiting two steps in bacterial folate biosynthesis. The lack of folate in 
bacteria  prevents  them  from  making  purine  bases,  blocking  DNA  synthesis  and 
blocking the biosynthesis of methionine, which in turn inhibits most methyltransferase 
reactions and prevents protein biosynthesis. The effects of these drugs is bacteriostatic 
and rarely bactericidal.14
  The  last  two  modes  of  action  involve  the  extracellular  targets  of  the  cell 
membrane  and cell  wall.  The inhibition of membrane function prevents cells from 
working properly by disrupting ion gradients and causing leakage of cellular materials. 
Daptomycin binds to Ca2+ then penetrates the cellular membrane, forming pores. The 
resulting membrane depolarization disrupts cellular metabolism.15 Polymyxin, due to 
its  positive  charge,  binds  to  phospholipids  and  lipopolysaccharide  causing  the 
disruption  of  both  membranes of  Gram-negative  bacteria.16  The  disruption  of  the 
bacterial  membrane  results  in  leakage  of  cellular  components  and  possible  lysis 
resulting in cell death. Antibiotics targeting the cellular membrane tend to have issues 
with toxicity to mammalian cells. 
  The disruption of cell wall biosynthesis has been a common target against Gram-
positive bacteria. The penicillins block the  transpeptidation  reaction  preventing  the 
cross-linking  of peptidoglycan and  formation of the cell  wall.3 Vancomycin blocks 
transglycosylation by binding to the D-Ala-D-Ala terminus of Lipid II and also inhibits 
the cross-linking of peptidoglycan strands by transpeptidases (Fig. 1.3).17 Fosfomycin, 
a  phosphoenolpyruvate  (PEP)  mimetic,  inhibits  MurA  (the  first  enzyme  in 
5peptidoglycan biosynthesis) by covalently binding  the active site  Cys, blocking  the 
transfer  of  PEP  to  the  3’-hydroxyl  group  of  UDP-N-Ac-glucosamine,  the  first 
committed step in peptidoglycan biosynthesis.18  
Drug Resistance
  For each of the modes of action, resistance mechanisms have evolved due to the 
inherent  selective  pressure  of  antibiotics.  Beta-lactam  antibiotics,  as  an  example, 
induce, in resistant strains, the production of PBPs with lower beta-lactam affinity or 
beta-lactamases that degrade  the  antibiotic.19 It is important to  note  that penicillin 
resistance  mechanisms  evolved  over  millions  of  years  not  just  the  6  years  of 
therapeutic  use  required for  ~40%  of  hospital  S.  aureus  isolates to  have  acquired 
resistance.20 The beta-lactamases are estimated to have evolved 2 billion years ago, 
prior to the divergence of Gram-negative and Gram-positive bacteria.21 Erythromycin 
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Figure 1.3 Key steps in cell wall biosynthesis by Gram positive bacteria with the vancomycin 
recognition element, D-Ala-D-Ala, highlighted in green.resistance results from a post-transcriptional methylation of adenosine  2058 on 23S 
rRNA of  the  50S  ribosomal  subunit causing  a  decrease  in binding  affinity.22  One 
general form of resistance is the development of drug efflux pumps by bacteria. Some 
efflux  systems  like  AcrAB-TolC  and  NormM from  E.  coli  can  transport various 
antibiotics out of the cell using  an ion gradient (Fig. 1.4). Others like MacAB only 
transport specific classes of compounds, i.e. macrolides, and require consumption of 
ATP.23  The  acquisition  of  drug  efflux  pumps  can  confer  multi-drug  resistance  to 
pathogenic bacterial strains and is one down side to inhibiting intracellular targets.24  
 G l y c o p e p t i d e   r e s i s t a n c e   i s   a n   i n s t r u c t i v e   e x a m p l e   w h e n   e x a m i n i n g   t h e  
acquisition of drug resistance genes. Clinical bacterial isolates resistant to vancomycin 
were not observed until nearly 40 years after its introduction.20 Resistance arose from 
the alteration of the  D-Ala-D-Ala terminus of Lipid II to D-Ala-D-Lactate causing a 
1000-fold decrease in vancomycin binding affinity.25 The strong selective pressure of 
vancomycin and other glycopeptides resulted in the acquisition of the vanRSHAX gene 
cluster  encoding  a  two  component regulatory system  (VanR  and VanS)  and  three 
enzymes used to install the new Lipid II peptide terminus (Fig. 1.5). The resistance 
gene cluster is found in numerous environmental bacteria and is likely the source of 
resistance  genes  found  in  pathogenic  bacteria.  Comparison  of  GC  content  of  the 
resistance  cluster  from  vancomycin  resistant  Enterococci ( V R E ) ,  4 0 % ,  a n d  
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being  the  most  common  in  gram-negative  bacteria) 
move from organism to organism on class 1 and 2 inte-
grons. dfr1 is present on the Tn7 transposon, thereby 
facilitating its integration into the E. coli chromosome.
Fluoroquinolones
The  plasmid-speciﬁed  qnr  determinants  provide  an 
unusual mechanism of decreased ﬂuoroquinolone sus-
ceptibility. Variants of the qnr element, ﬁrst identiﬁed in 
K.  pneumoniae  (Martinez-Martinez  et  al.,  1998),  have 
been found in E. coli, Enterobacter cloacae, Providencia 
stuartii, Citrobacter freundii, C. koseri, Shigella ﬂexneri 
2b, and non-Typhi Salmonella enterica. Qnr belongs to 
the  pentapeptide  repeat  family  of  proteins  and  medi-
ates resistance presumably by protecting DNA gyrase 
and topoisomerase IV from the inhibitory action of the 
ﬂuoroquinolones (Tran and Jacoby, 2002). Another ﬂuo-
roquinolone  resistance  mechanism,  MfpA,  has  been 
found in M. tuberculosis, which contains a single type II 
topoisomerase (Hegde et al., 2005). It, too, is a member 
of the pentapeptide repeat family of proteins but also 
acts as an inhibitor of DNA gyrase from M. tuberculosis 
by virtue of its ability to mimic the structure of B-form 
DNA.  The  interaction  of  MfpA  with  DNA  gyrase  likely 
interferes with the inhibitory action of agents like cipro-
ﬂoxacin. By themselves, Qnr and MfpA confer only low 
levels  of  ﬂuoroquinolone  resistance  but  can  augment 
resistance when coupled with other mechanisms (see 
below). Moreover, selection for ﬂuoroquinolone resist-
ance may be favored in organisms bearing Qnr or MfpA 
if they survive the presence of low ﬂuoroquinolone con-
centrations.
Efﬂux Systems, Porins, and Altered Membranes
Efﬂux  as  a  mechanism  of  antibiotic  resistance  was 
originally described for tetracyclines (McMurry et al., 
1980)  and  is  now  well-appreciated  and  commonly 
found. Most drug efﬂux proteins belong to ﬁve dis-
tinct  protein  families:  the  resistance-nodulation-cell 
division (RND), major facilitator (MF), staphylococcal/
small multidrug resistance (SMR), ATP-binding cas-
sette (ABC), and multidrug and toxic compound extru-
sion (MATE) families (Li and Nikaido, 2004). Efﬂux by 
proteins in the RND, SMR, MF, and MATE families is 
driven  by  proton  (and  sodium)  motive  force  and  is 
therefore called secondary transport (Figure 3). ATP 
hydrolysis drives efﬂux in the primary (ABC) transport-
ers (Figure 3). Efﬂux proteins also come in two general 
types.  Some,  like  the  tetracycline  (Tet)  (Levy,  1992) 
and macrolide (Mef) (Zhanel et al., 2001) transporters, 
are single component efﬂux systems that have narrow 
substrate proﬁles, acting on a few agents or multiple 
agents within the same drug class. Others, such as 
the RND family members, require two additional pro-
teins to confer resistance but are capable of binding 
multiple structurally unrelated compounds and confer 
broad resistance phenotypes (Li and Nikaido, 2004). 
The organizations of the RND-based efﬂux systems, 
which are found in a number of gram-negative bacte-
ria, allow them to transport drugs from the cytoplasm 
and across the inner and outer membranes of the cell 
envelope (Figure 3).
Tetracyclines
There are now more than 20 different tetracycline efﬂux 
proteins that have been allocated to six different groups 
(Sapunaric et al., 2005). The proteins contain either 12- 
(e.g., TetA-E in gram-negative bacteria) or 14- (e.g., TetK 
and  TetL  in  gram-positive  organisms)  putative  trans-
membrane-spanning segments. Expression of proteins 
within group 1 is controlled by a transcription repressor 
such as TetR. The antibiotic inactivates the repressor 
and allows expression of the tetracycline efﬂux systems. 
Alternatively, synthesis of TetK and TetL is inducible by 
tetracyclines  through  mechanisms  that  involve  trans-
lation  attenuation  and  reinitiation,  respectively.  Also, 
the mechanism of tetracycline efﬂux is not conserved 
among all members; some, such as Tet(B), engage in 
electroneutral  reactions  (that  is,  one  tetracycline-Mg 
chelate exits the cell as a proton enters whereas others, 
such as TetL, accomplish efﬂux in an electrogenic man-
ner [references in Sapunaric et al., 2005]).
Figure 3. Antibiotic Efﬂux Systems
For  simplicity,  the  illustration  represents  a 
gram-negative  bacterium.  Some  substrates 
of AcrAB (e.g., aminoglycosides) are presum-
ably  recognized  by  a  portion  of  AcrB  that 
faces the cytoplasm while others (e.g., tetra-
cycline) migrate thorough the inner membrane 
to an AcrB-binding pocket(s) (Murakami and 
Yamaguchi,  2003).  The  E.  coli  AcrAB-TolC 
and Tet efﬂux systems are secondary trans-
porters that use proton motive force (H+) while 
NorM (Vibrio spp.) is a secondary transporter 
that exploits a gradient of sodium ions (Na+) 
to drive efﬂux (Li and Nikaido, 2004). MacAB 
is a primary transporter that uses the energy 
derived from ATP hydrolysis to drive efﬂux (Li 
and  Nikaido,  2004).  Single-component  sys-
tems  (e.g.,  NorM,  Tet)  transport  substrates 
across the inner membrane where they then 
diffuse  through  porins  (e.g.,  OmpF)  or  the 
outer membrane into the extracellular medium (Li and Nikaido, 2004). Multicomponent systems like AcrAB-TolC and MacAB-TolC direct the 
transport of substrates to the extracellular medium. Abbreviations: LPS, lipopolysaccharide; Ab, antibiotic; Tc, tetracycline; Mac, macrolide.
Figure 1.4 A Gram-negative membrane complex illustrating four drug efflux pumps: AcrAB-
TolC, MacAB-TolC, NorM and Tet. Both NorM and Tet rely on passive transporters  like the 
porin OmpF for removal of the drug from the periplasm. Figure from Alekshun et al.24Streptomyces strains, 70%, indicates the gene cluster has had significant time for the 
drift of GC content. The gene cluster has been outside of the vancomycin-producing 
bacteria for a significant time since  the  evolution of vancomycin an estimated 240 
million years ago.  For many antibiotics the  resistance mechanism  already exists in 
non-pathogenic bacteria. The primary concern is the transfer of resistance genes into 
pathogenic strains.
  The  improper  use  of  antibiotics  causes  selective  pressures  for  pathogens  to 
acquire resistance genes. Overprescription and patient noncompliance have resulted in 
extensive  drug  resistance  in  some  pathogens.26  The  long  patient  compliance 
requirements for effective treatment of TB has aided in the propagation of multi-drug-
resistant  Mycobacterium  tuberculosis  (MDR-TB).27  A  survey  of  58  geographical 
regions indicated 0-16% (1% median) of total new infections and 0-48% (9% median) 
of  recurrent  cases  were  MDR-TB.  The  highest  incidence  MDR-TB  occur  in  the 
undeveloped regions of the survey due to incomplete treatment regimens.28 
  Outside of the clinical setting, the use of antibiotics in the agricultural industry 
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Figure 1.5 A)  Structure of vancomycin showing the five hydrogen bonds  formed with the D-
Ala-D-Ala terminus of Lipid II. B) The vancomycin resistance genes and their corresponding 
functions in producing D-Ala-D-Lac Lipid II. Figure from Wright.46has lead to  further issues of drug  resistance. Chlamydia trachomatis is an obligate 
intracellular Gram-negative  pathogen. Human chlamydial infections have long  been 
treated with tetracycline without the emergence of antibiotic resistance. However, a 
series  of  Chlymadia  suis  strains  from  pigs  has  been  documented  as  having  a 
transferrable genomic island containing tetracycline resistance genes.29 The emergence 
of these resistant strains is attributed to the extensive use of tetracycline-containing 
feed additives in the U.S. and Europe.30  
 T o   c o m b a t   d r u g   r e s i s t a n c e ,   s e v e r a l   a p p r o a c h e s   h a v e   b e e n   t a k e n .   T h e  
modification  of  existing  drugs  to  avoid  or  adapt  to  the  resistance  mechanism  is 
exemplified  by the development of methicillin.  Resistance  to penicillin G through 
beta-lactamases led to the search for a beta-lactamase-resistant penicillin. From this 
semisynthetic  discovery  program  came  methicillin.  Alternately,  the  use  of  beta-
lactamase inhibitors such as clavulanic acid has been employed to retain sensitivity to 
beta-lactams  by  some  penicillin-resistant  pathogens  (Fig.  1.6).  The  specter  of 
antibiotic resistance has continually spurred the search for new antibiotic compounds. 
However,  as  the  number  of  new  chemical  entities  discovered  has  declined,  the 
reevaluation and repurposing of previously discovered antibiotics has become more 
important. Compounds such as the  aminoglycosides, omitted  from  use as first line 
antibiotics  due  to  toxicity  and  physical  properties,  are  finding  increasing  use 
combating drug resistant infections.31 Advances in bacterial genetics, biochemistry and 
synthetic chemistry bring the potential for the optimization of previously discovered 
antibiotic classes to combat drug resistance. Enduracidin has a high potential to fulfill 
this objective.
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Figure 1.6 Structures of A) Methicillin, B) Penicillin G and C) Clavulanic acid.Enduracidin, History and Potential
  Enduracidin was discovered in 1968 through an antibiotic screening program by 
Takeda  industries  in  Japan.32  The  soil  bacterium  Streptomyces  fungicidicus w a s  
isolated  and  found  to  produce  the  highly active  compound.33  The  compound  was 
analyzed and found to be a large lipodepsipeptide containing several nonproteinogenic 
amino acids. The structure was elucidated in 1973 (Fig. 1.7).34 
  Initial work on the mechanism of action showed that enduracidin inhibited cell 
wall  biosynthesis.35  In  further  studies  a  marked  increase  in  UDP-Mur-NAc 
pentapeptide was thought to indicate that Lipid I was the binding site, thus inhibiting 
MurG.36  Further  work  indicated  that enduracidin  bound  specifically to  Lipid  II.37 
Crystal  structures  and  NMR  data  demonstrated  that  enduracidin  and  the  related 
compound  ramoplanin  bind  as  a  dimer  to  the  sugar  diphosphate  linkage  on  the 
proximal end of Lipid II (Fig. 1.8).38 The enduracidin mechanism of action is shared 
only  by  nisin  and  a  few  related  lantibiotics.39  Nisin,  in  addition  to  blocking 
transglycosylation  by binding  to  the  diphosphate  of  Lipid  II,  forms  pores  in  the 
membrane.40 Like vancomycin, enduracidin and ramoplanin inhibit transglycosylation, 
blocking  peptidoglycan biosynthesis. Due to their distinct binding sites, enduracidin 
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Figure 1.7 The structure of enduracidin A and B.
Enduracidin A: R = H 
Enduracidin B: R = CH3and ramoplanin are active against MRSA and VRE.37c, 41 Additionally there has been 
no observed transferrable  resistance mechanism or cross resistance  for enduracidin 
despite being used for over three decades as a poultry feed additive.17, 42 
  Enduracidin  was  evaluated  for  use  as  a  human  therapeutic  soon  after  its 
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Structure and conformation of enduracidin 609
After minimization, none of the representative struc-
tures was found to respect signiﬁcantly all the experi-
mentally determined NOE distances. Therefore, a second
MD simulation-based reﬁnement was run, starting from the
representative structure of the most populated cluster. Also
in this MD reﬁnement, the experimentally determined NOE
restrained were imposed on the molecule with a restrain-
ing potential of 20 kJ mol
 1.T h es i m u l a t i o np r o t o c o lw a s
the same as described above (see Fig. 5). The 2500 struc-
tures obtained from this second simulation were subjected
to cluster analysis, with a cut-off distance of 1 ˚ A, and only
one signiﬁcantly populated cluster was obtained. The rep-
resentative structure of this cluster was shown to respect
all the experimental NOE distance restraints. The most
representative structure of this cluster was minimized with-
out any restraints until the convergence criterion for the
gradient was satisﬁed (gradient <0.05 kJ mol
 1 ˚ A
 1
). The
minimized structure is still consistent with all NMR-derived
NOE restraints.
DISCUSSION
The combination of NMR restraints and modeling data
provided an atomic representation of the three-dimensional
structure of enduracidin.
The overall backbone structure of enduracidin and of
the closely related antibiotic ramoplanin shares a high
degreeofsimilarity. Bothstructuresarecharacterizedbytwo
antiparallelˇ-strands.Inenduracidinthetwostrandsinclude
residues 5–7 and 10–12, connected by a turn including the
residues 8 and 9 (Fig. 4). Hydrogen bonding interactions are
between Thr5 and Ser12, Hpg7 and Orn10, and Hpg7 and
Cit9 (Fig. 4).
Residues5and12,inthecyclicarchitectureofthepeptide,
are connected by a large loop containing the lactone bond
between the carboxy group of Hpg17 and the hydroxyl
moiety of Thr2. This overall conservation of the topology,
with respect to the highly homologous ramoplanin, should
not be unexpected.
Leu 15 Ala 16
Hydrophobic Core
Hpg 17
Hpg 3
Hpg 3 Phe 9
Thr 12
Hpg 13
Ramoplanin A2
End 15
Hpg 17
Ala 16
Lactone Junction
Cit 9
Turn region
Enduracidin A
Ser 12
Dpg 13
Figure 4. 3D structures of the two antibiotic molecules ramoplanin A2 and enduracidin A. Circles highlight the main regions
discussed in the text. Dotted lines represent intramolecular hydrogen bonding interactions.
Ramoplanin Enduracidin
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Acyl Chain
Acyl Chain
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Figure 5. Structural differences between ramoplanin and enduracidin. Thel a t t e re x p o s e st h es i d e - c h a i no fc i t r u l l i n et ot h es o l v e n t ,
whereas the former is characterized by a well-packed hydrophobicc o r e ,s t a b i l i z e db yt h ep a c k i n go ft h r e ea r o m a t i cr e s i d u e s( H p g 3 ,
Phe9 and Chp17) with the acyl side-chain of the fatty moiety.
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Figure  1.8  A)  Peptidoglycan  biosynthesis  with  the  vancomycin  (green)  and  enduracidin 
(purple)  recognition  elements  highlighted.  B)  3D  NMR  structure  of  enduracidin  from 
Castiglione et al.38b C) Crystal structure of a ramoplanin dimer (yellow and purple) interfacing 
with detergent molecules (green), chloride ions (magenta) and ordered water molecules (red) 
figure is from Hamburger et al.38c
A
B Cdiscovery.43 As a large peptide, enduracidin had no oral bioavailability so the use of 
enduracidin as an IV or intramuscularly (IM) injected drug was also evaluated.42,  44 
The low solubility in blood plasma led to the testing of enduracidin for IM injection as 
a  suspension  in  nonionic  detergents.  The  results  indicated  an  unacceptable 
accumulation  effect  was  occurring,  likely  resulting  from  precipitation.45 T h e  
insolubility of enduracidin resulted in it being allocated into use as a feed additive in 
the 1980s. 
  As the prevalence of antibiotic resistance continues to grow, new therapeutics are 
needed. The reevaluation of previously discovered antimicrobials provides a wealth of 
active compounds for development.31 Compounds put aside due to pharmacological 
properties or toxicity can now be modified using the advances in microbial genetics, 
biosynthesis  and  chemistry  achieved  in  the  past  20  years.  Alteration  of  the 
pharmacological  properties  of  enduracidin  can  potentially  produce  a  superior 
antibiotic for the treatment of drug-resistant Gram-positive bacterial infections. The 
work of this thesis has focused on understanding the biosynthesis of enduracidin, then 
utilizing  the  biosynthetic  pathways  and  chemical  synthesis  to  alter  the  physical 
properties of enduracidin, improving solubility while maintaining bioactivity.
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18CHAPTER TWO
MUTASYNTHETIC MODIFICATION OF ENDURACIDIN
Neal GoebelIntroduction
 E n d u r a c i d i n   c o n t a i n s   f i v e   h y d r o x y p h e n y l g l y c i n e s   ( H p g )   a n d   o n e  
dichlorohydroxyphenylglycine (Dpg) (Fig. 2.1). Structural studies of enduracidin have 
shown that the Hpg-3 hydroxyl group is involved in an intramolecular hydrogen bond 
important for conformation while Hpgs 6, 7, 11, 17 and Dpg-13 primarily interact with 
the  solvent environment.1 The  number and distribution of Hpg  residues throughout 
enduracidin  make  them  a  relevant  target  for  modulating  enduracidin’s  physical 
properties. The introduction of fluorine onto the phenol group of Hpg was selected to 
begin this study as it is metabolically stable and the minimal increase in steric bulk 
may  reduce  alterations  in  structural  conformation,  minimizing  the  reduction  of 
bioactivity. Additionally, the electron-withdrawing  nature of fluorine can reduce the 
pKa of the phenolic hydroxyl  proton.2 A pKa  near biologically relevant ranges may 
improve solvation around the six Hpg-derived groups. 
   In S. fungicidicus, the enduracidin biosynthetic gene cluster contains the genes 
coding for the enzymes required to convert hydroxyphenylpyruvate and tyrosine into 
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Figure 2.1 The structure of enduracidins A and B with the five hydroxyphenylglycines and 
one dichlorohydroxyphenylglycine labeled.
1 Enduracidin A: R = H 
2 Enduracidin B: R = CH3Hpg (Fig. 2.2).3 The localization of Hpg biosynthetic genes in the enduracidin gene 
cluster  suggests  that  Hpg  production  is  not  essential  for  other  S.  fungicidicus 
metabolites and is therefore an exploitable route for the alteration of enduracidin 
without  disrupting  other  metabolic  pathways.  This work  aims  to  demonstrate  the 
ability  to  produce  new  enduracidin  analogs  with  altered  physical  properties  by 
manipulating the hydroxyphenylglycine biosynthetic pathway.
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Figure  2.2  Biosynthesis  of  hydroxyphenylglycine  in  S.  fungicidicus s t a r t i n g  f r o m  
prephenate.Results and Discussion
  The phenol ring  of tyrosine is not modified during  its conversion to Hpg  (Fig. 
2.2)  suggesting  that  3-fluoro-hydroxyphenylglycine  (3-F-Hpg)  may  be  produced 
intracellularly if  3-fluoro-tyrosine  (F-Tyr)  could  serve  as a  precursor  via  the  Hpg 
biosynthetic  enzymes.  To  demonstrate  F-Hpg  can  be  produced  from  F-Tyr  and 
incorporated into enduracidin, cultures of S. fungicidicus were supplemented with a 
racemic  mixture  of  DL-F-Tyr.  The  cultures  produced  a  series  of  polyfluorinated 
enduracidins as evidenced by ESI-MS (Fig. 2.3). The fluorine incorporation produced 
a series of compounds ranging from difluoro-monochloro enduracidin A (m/z=1178.5) 
to 3’-hexafluoro-monochloro enduracidin A (3’-F6-Cl1 end A) (m/z=1214.5) as well as 
pentafluoro-dichloro  enduracidin (m/z=1222.5). Interestingly, in this experiment the 
presence of fluorine did not inhibit the halogenase, resulting in the formation of a 3-
chloro-5-fluoro-Hpg  instead  of  3-F-Hpg-13.4  The  incorporation  of  fluorine  into 
enduracidin  demonstrated  that  the  biosynthesis  of  Hpg  was  not  disrupted  by the 
presence of fluorine on the phenol moiety. Additionally, the production of hexafluoro-
monochloro-enduracidin  indicated  the  binding  pockets  of  the  Hpg  adenylation 
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Figure  2.3  ESI  positive  mass  spectrum  showing  the  [M+2H]2+  ions  of  polyfluorinated 
enduracidins produced from F-Tyr supplementationdomains tolerate the altered electronegativity and steric bulk of fluorinated Hpg. The 
mixture of polyfluorinated enduracidins proved to be inseparable via chromatographic 
means, prohibiting studies on individual species. 
  In  an attempt to  reduce  the  number of  fluorinated  enduracidin  species being 
produced we  undertook  the  preparation  of  3-F-Hpg  (7a)  starting  from  3-fluoro-4-
methoxybenzaldehyde (3a) (Fig. 2.4). A modified Strecker reaction utilizing, TMS-
cyanide,  benzylamine,  and  catalytic  cyanuric  chloride  successfully yielded  the  N-
benzyl aminonitrile (4a).5 To prevent degradation during hydrolysis of the nitrile, (4a) 
was first treated with formic-acetic anhydride, then heated in the presence of HCl to 
yield  the  N-benzyl  amino  acid  (5a).6 W i t h o u t  f u r t h e r  p u r i f i c a t i o n ,  t h e  
methoxyphenylglycine  (5a)  was  converted  to  the  hydroxyphenylglycine  (6a)  with 
concentrated HBr under refluxing conditions. Deprotection of the N-benzyl group via 
palladium-catalyzed  transfer  hydrogenation  followed  by crystallization  from  water 
afforded racemic DL-3-F-Hpg (7a) in 31% overall yield.
  Supplementation of wild type cultures of S. fungicidicus with 3-F-Hpg produced 
a  series  of  fluorinated  enduracidins  as  observed  via  MALDI  MS  (Fig  2.5).  The 
introduction of fluorine via F-Hpg, rather than F-Tyr, improved the production of the 
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Figure 2.4 Preparation of fluoro-Hpg from fluorobenzaldehyde. For n=1 fluorine is in the 2 or 3 
position as specified. For n=2 fluorine is in the 2 and 5 positions.
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d: X = 3-Clhexafluoro species. Interestingly, a series of deschloro fluorinated enduracidin species 
was also produced, as well as deschloro enduracin. The data showed that F-Hpg was 
readily  incorporated  into  enduracidin.  However,  even  at  high  levels  of 
supplementation, a single hexafluoro enduracidin species was not produced.
  To solely produce the 3’-hexafluoro enduracidin species we aimed to eliminate 
the endogenous production of Hpg and complement the deficiency with exogenous 3-
F-Hpg. The gene product of orf29 is predicted to be a fusion protein homologous to 
both the p-hydroxymandelate oxidase (HmO) and the aminotransferase (HpgT) from 
S.  coelicolor  and  involved  in  Hpg  biosynthesis  (Fig.  2.2).3,  7  To prevent possible 
consumption of 3-F-Hpg via transamination, the aminotranferase portion of orf29 was 
targeted for disruption. The gene disruption delivery fosmid pXYF148D3, containing 
the  disruption  cassette  Tn5AT,  was  introduced  into  wild-type  S.  fungicidicus  via 
conjugation  (Fig.  2.6).  Exconjugants  demonstrating  double  crossover  homologous 
recombination  via  retained  apramycin  resistance  were  verified  for  insertional 
disruption of orf29 by Southern blot analysis of the chromosomal DNA. The disrupted 
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Figure 2.5 MALDI Mass spectrum of enduracidins isolated from SfWT supplemented with 3-
F-Hpg showing the [M+H]+ ions.25
Figure 2.6 I) Insertional disruption of orf29 using the apramycin resistance gene aac(3)IV 
and Southern blot test confirming disruption. II) HPLC chromatogram of mycelia extracts 
from: A) SfWT, B) Sforf29::Tn5AT, C) Sforf29::Tn5AT + Hpg and D) Sforf29::Tn5AT + F-
Hpg. Enduracidin A and B are indicated by red asterisks  and 3'-F6  enduracidin A and B 
are indicated with blue asterisks.
II
Istrains were designated Sforf29::Tn5AT. HPLC analysis of Sforf29::Tn5AT mycelia 
extract indicated the orf29 disruptant was unable to produce enduracidin (Fig. 2.6B). 
Furthermore,  production  was  restored  when  cultures  of  the  disruptant  were 
supplemented with Hpg, demonstrating the gene disruption affected Hpg biosynthesis 
(Fig. 2.6C). 
  The Sforf29::Tn5AT strain, when supplemented with 3-F-Hpg, produced a new 
set of enduracidins having  HPLC retention times of 15.4 and 16.5 min. (Fig. 2.6D). 
The isolated peaks, when analyzed via ESI-MS, showed molecular weights of 2427 
and 2393 Da for the first peak (15.4 min) and 2407 and 2441 Da in the second peak 
(16.5 min) (Fig. 2.7). The compounds were likely the previously observed 3’-F6-Cl1 
enduracidin A and B and the new set of 3’-hexafluoro-deschloroenduracidin A (3’-F6-
Cl0 end A) and B. Further HPLC purification separated the deschloro and monochloro 
species allowing  for characterization of  each compound.  NMR  spectra  for  the  3’-
hexafluoroenduracidin species show a high similarity to natural enduracidin A in the 
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Figure 2.7 ESI positive MS of 3’-F6 enduracidins A and B showing the [M+2H]2+ ions. The m/z 
peak  groups  at  1197.5  and1204.5 correspond to  deschloro species  while the 1214.5 and 
1221.5 peak groups are the monochloro species.upfield region.   The  aromatic region,  however,  showed  a  significant difference in 
chemical shifts and splitting due to the presence of aryl-bound fluorine (Fig. 2.8A and 
B). These alterations are also observed in the 1H-1H COSY spectra (Fig. 2.8D and E). 
The  incorporation of six  fluorine  atoms bound to aryl  rings was confirmed by 19F-
NMR. The spectrum shows four distinct resonances and two overlapping signals (Fig. 
2.8C). 
  To further examine the ability to biosynthetically incorporate Hpg analogs into 
enduracidin, 2-F-Hpg and 2,6-F2-Hpg  were  prepared using  the previously described 
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Figure 2.8 A) Enduracidin A 1H-NMR spectrum B) 3’-F6-Cl1-End A 1H-NMR spectrum C) 19F-
NMR spectrum of 3’-F6-Cl1 End A D) Aromatic region of COSY spectrum of enduracidin A E) 
Aromatic region of 3'-F6-Cl1 End A. Hpg correlations are indicated with asterisks.procedure  (Fig.  2.4).  Additionally,  L-3-nitro-Hpg  was  prepared  from  L-Hpg  via 
nitration of the trifluoroacetamide  protected Hpg  methyl ester (9) using AcOH and 
NaNO2.8 Deprotection via acid hydrolysis afforded 3-nitro-Hpg  in 56% overall yield 
(Fig. 2.9). 
  Analysis of mycelial extracts from cultures supplemented with 2,6-F2-Hpg and 
3-nitro-Hpg indicated no new enduracidin species were produced (Fig. 2.10 B and D). 
Enduracidin production was restored when cultures were supplemented with both 2,6-
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Figure 2.10 HPLC chromatogram showing A)  Enduracidin standard, B) Sforf29::Tn5AT + 3-
nitro Hpg,  C)  Sforf29::Tn5AT + 3-nitro  Hpg and Hpg  D)  Sforf29::Tn5AT + 2,6-F2  Hpg,  E) 
Sforf29::Tn5AT + 2,6-F2 Hpg and Hpg. Enduracidin A (left asterisk) merges  with a common 
metabolite  peak  in  chromatogram  E.  Enduracidin  B  (right  asterisk)  is  also  present  in 
chromatogram E.
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Figure 2.9 Preparation of 3-nitro Hpg via aromatic nitration. 
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8 9 10 11F2 Hpg and L-Hpg. HPLC retention time indicated there was no fluorine incorporation. 
Cultures  supplemented  with  3-nitro  Hpg  and  L-Hpg  were  unable  to  produce 
enduracidin (Figure 2.10 C). These data suggest that 3-nitro Hpg may be disrupting 
enduracidin production. However, Sforf29::Tn5AT cultures were observed to produce 
new enduracidin species when supplemented with 2-F-Hpg (Fig. 2.11 I). 
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Figure 2.11 I) HPLC chromatogram of mycelial extract of Sforf29::Tn5AT supplemented with 2-
F  Hpg. Letters  indicate the four  enduracidin analogs  present.  II)  ESI  positive  MS  spectra 
showing [M+2H]2+  ions  for  each of the peaks  A)  m/z = 1214.5, 2'-F6-Cl1  End A, B)  m/z  = 
1231.5, 2'-F6-Cl2 End A, C) m/z = 1221.5, 2'-F6-Cl1 End B and D) m/z = 1238.5, 2'-F6-Cl2 End 
B.
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II  Isolation  and  MS  analysis  of  the  peaks  indicated  the  production  of  2’-
hexfluoromonochloro (2’-F6-Cl1 End) and 2’-hexafluorodichloro enduracidin (2’-F6-
Cl2  End)  analogs  (Fig.  2.11  II).  To  deduce  the  chlorine  position  in  2’-F6-Cl1 
enduracidin the 1H-1H COSY spectra of the mono and dichloro species were examined 
(Figure 2.12 A and B). Due to the overlap of signals the loss or shift of an individual 
signal corresponding to the addition of a chlorine was not observed. Examination of 
the 19F NMR spectra provided some evidence for the location of the chlorine on 2’-F6-
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Figure 2.12 COSY spectra for A) 2’-F6-Cl1 End B and B) 2’-F6-Cl2 End B. Spectra showing the 
19F NMR signals for C) 2’-F6-Cl1 End B and D) 2’-F6-Cl2 End B.
A
B
C
DCl1 End (Fig  2.12 C). Software calculations predict an approximate +7 ppm shift to 
approximately -109 ppm for the 19F signal of 2-F-3-Cl Hpg compared to the -116 ppm 
shift for 2-F-5-Cl-Hpg. With the spectroscopic data providing  insufficient evidence, 
the position of chlorination was examined from a biosynthetic aspect. The enduracidin 
chlorinase  (Orf30)  is a  flavin  dependent  halogenase.3, 9 Recent  crystallization  and 
biochemical work with the tyrosine chlorinase enzyme CndH (53% identity to Orf30) 
indicated  the  enzyme  functions  via  hypochlorite  formation  using  a  FAD  peroxide 
intermediate. The  hypochlorite  is  then  postulated to travel  through a  tunnel in the 
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Figure  2.13  Amino  acid  alignment  of  the  flavin-dependent  halogenases  Orf30  from  S. 
fungicidicus and CndH from Chondromyces crocatus. The sequences share 53% identity and 
67% similarity. The residues highlighted in red, including lysine 76, are directly involved with 
reactivity.  Those  in  blue  designate  key  residues  forming  the  binding pocket.  The  yellow 
sequence is  a  portion of the tunnel allowing hypochlorite to travel to the active site. The 
conserved GWxWxI sequence is used as a fingerprint to identify this class of halogenase.enzyme and form a chloramine intermediate with lysine 76 within the active site, a 
conserved feature of this family of enzymes.10 The key amino acid residues forming 
the active site, including lysine 76, are conserved in Orf30 (Fig. 2.13).11 
  To begin understanding  the influence of ring  substitution on reactivity, charge 
localization calculations were made. Reduced partial negative charge was predicted on 
C-3 of 2-F-Hpg compared to C-5 of 3-F-Hpg and 3-Cl-Hpg (Fig. 2.14). The presence 
of fluorine in the three position of Hpg may prevent halogenation as evidenced by the 
reduced charge and production of 3-F6-Cl0 End. HOMO modeling of 2-F-Hpg and 2-
F-5-Cl-Hpg showed that the reactive orbital is shifted away from C-3 in both cases. 
C-5 of 2-F-Hpg, however, is calculated to have a minimal reduction in partial negative 
charge and increased HOMO density. The reduced partial charge and HOMO density 
on the  3-carbon,  coupled  with  the  lack of  19F NMR shifts  near  -109  ppm  for the 
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Figure 2.14 HOMO maps  of the possible substrates  for the halogenase Orf30. The values 
represent the calculated charge present on the potentially chlorinated carbon. isolated compound, suggests that chlorination occurs at the 5’ position of residue-13. 
Interestingly, the  19F NMR spectrum  for 2’-F6-Cl2-enduracidin also lacks a  fluorine 
peak with a  shift  near  the  -109  ppm  region  (Fig  2.12D). MS/MS  analysis of  the 
dichloro  species  has  been  unsuccessful.  From  previous  work  enduracidin  was 
successfully halogenated on Hpg-11.4 It is possible that the  halogenation occurs on 
residue-13 and  Hpg-11 both  in the 5’-position. The  ability of Orf30 to  halogenate 
other Hpg  residues  was noted by the  observation  of  a  small  amount of  3’-F6-Cl2 
Enduracidins A and B by MS (Fig. 2.15).
  Other  Hpg  analogs  were  pursued  for  investigation.  After  the  successful 
incorporation of 3-F Hpg into enduracidin in the wild-type organism, the production of 
3-Cl  Hpg  was undertaken using  the same  synthetic scheme (Fig. 2.4). The desired 
product was not obtained, however, due to the dehalogenation reaction which occurred 
during  the  reductive  cleavage  of  the  benzyl  protecting  group.  To  explore  the 
incorporation of Cl-Hpg, cultures of S. fungicidicus were supplemented with 3-Cl Tyr, 
however  the  compound  proved  to  be  toxic.  Further  investigations  with  chlorine 
substitutions were not pursued. 
  The  substitution of a pyr group for the phenyl group was undertaken starting 
from 2-Me, 5-OBn pyridine  (Fig. 2.16 A). The production of the  aldehyde and the 
aminonitrile  proved successful using  standard procedures.13 However, hydrolysis of 
the  nitrile  to the  free  carboxylic  acid  resulted in decarboxylation when exposed to 
neutral pH (Fig. 2.16 B). As the compound proved unstable and shifting the pyridinyl 
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Figure  2.15  ESI  positive  mass  spectra  of  isolated  unknown  enduracidins  from  3-F  Hpg 
experiments showing 3’-F6-Cl2 enduracidin A (m/z = 1231.5) and B (m/z = 1238.5). nitrogen  to  the  3-position  would  potentially result  in  the  formation  of  a  reactive 
pyridinyl N-chloride species by the halogenase enzyme the concept was not pursued 
further.
  As the  structural alterations from  the introduction of fluorine into enduracidin 
may affect its conformation and thereby its bioactivity, a bioassay against S. aureus 
was  performed;  comparing  the  hexafluoroenduracidins  to  enduracidins  A,  B  and 
ampicillin (Fig 2.17 A).  The 3’-F6 enduracidins all exhibited MIC values of 0.4 µM, 
equivalent to enduracidins A and B (Fig 2.17 B). The 2’-F6 enduracidins, except 2’-F6-
Cl1 End B (0.4 µM), had a MIC of 0.8 µM (Fig  2.17 C). The bioactivity was only 
reduced by two-fold in the 2’-F6 analogs. Compared to the bioactivity of ampicillin 
(6.4 µM) in the same assay the reduction of bioactivity is minimal. The data indicate 
that the potency of enduracidin is slightly negatively affected by fluorination on the 2’ 
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Figure 2.16 A) Synthesis  of hydroxypyridinylglycine starting from 3-hydroxy-6-methylpyridine 
to the aminonitrile. B) Degradation of hydrolyzed amino nitrile results in the production of N-
benzyl-5-benzyloxypyridinyl-methylamine.
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Acarbon. The overall affect of fluorine on enduracidin appears to be minimal in terms of 
bioactivity. The size of the fluorine atom appears to minimally affect the conformation 
or binding  to the bacterial target. Interestingly, placement in the 2’ position affected 
bioactivity more. As  fluorine  at the  2’ position  has  less effect on  the  pKa  of  the 
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Figure 2.17 Growth inhibition assay against S. aureus for A) enduracidins A, B and Ampicillin, 
B) 3’-F6 enduracidins and C) 2’-F6 enduracidins.phenolic  proton  the  reduction  in  activity  is  likely  due  to  a  hindered  rotation/
positioning of the Hpgs in the tertiary peptide structure. The effects of the decreased 
phenolic proton pKa on the 3’-fluoro species appears to have had minimal or no effect 
on  bioactivity. The  intramolecular  hydrogen  bond  of  Hpg-3  also  appears  to  have 
minimal effect in modifying the bioactive structure of enduracidin. 
 T h e r e   a r e   l i m i t a t i o n s   t o   t h e   m u t a s y n t h e t i c   m o d i f i c a t i o n   o f   e n d u r a c i d i n .  
Specifically, the 2,6-F2-Hpg did not incorporate and the enduracidin production in the 
2-F-Hpg  supplemented cultures was highly reduced, to around 100 µg/L total 2‘-F6 
enduracidin, compared to a typical range of 5 to 50 mg/L of enduracidin production. 
The 3-F-Hpg supplementation led to better fluoroenduracidin production (1 mg/L). As 
production  yields  were  low,  sufficient  quantities  of  fluoroenduracidin  to  analyze 
solubility or to test in live animal studies to evaluate the pharmacokinetics were not 
available.  The  results  here,  however,  do indicate  a  that mutasynthetic  approach to 
altering enduracidin is a viable means for producing new bioactive analogs.
36Experimentral Procedures
Bacterial Strains, media and culture conditions
The wild type Streptomyces fungicidicus strain (ATCC21013)  and S. aureus (ATCC 
29213) were purchased from ATCC. EPI300TM-T1R (Epicentre) was used as host for 
fosmids and E. coli-Streptomyces shuttle vectors. The plasmid pIJ773 was provided by 
Professor  Keith  Chater  (JIC,  Norwich,  England).  ISP2  (Difco),  ISP4  (Difco)  and 
tryptic soy broth (Difco) and other media components were purchased from VWR. For 
initial  fluorine  incorporation  studies  DL-3-F-tyrosine  was  purchased  from  Sigma. 
Media and culture conditions for S. fungicidicus were as previously described.12
Extraction method
Production cultures were  centrifuged at 1500 × g for 30 min. The supernatant was 
decanted and the pellet extracted with 70% aq. methanol overnight. Insoluble material 
was  removed  via  centrifugation  and  the  extract  was  decanted.  The  solvent  was 
removed under reduced pressure and the solids were redissolved in minimal 70% aq. 
methanol for analysis or purification. 
Construction of the Tn5AT cassette and fosmid pXYF148D3
Both oriT and aaC3(IV) (AT) were excised from plasmid pIJ773 as a XbaI fragment 
and  then cloned  into  the  transposon  donor plasmid  pMODTM-2(MCS)  (Epicentre), 
previously  linearized  with  XbaI.  The  resulting  plasmids  pXYTn5ATa  and 
pXYTn5ATb  only differ  in the  orientation of the XbaI  fragment and  were used to 
prepare the Tn5AT cassette by digestion with PvuII. Transposon insertional mutation 
of fosmid pXYF1483 was performed at 37 °C for 2 hrs after mixing 10 µL (0.5 µg) 
fosmid template DNA, 2 µL (20 ng) Tn5AT cassette DNA, 2 µL10 x reaction buffer, 1 
µL Tn5 transposase and 5 µL sterile water. Transformation of E. coli competent cells 
EPI300TM-T1R  (Epicentre) with the  transposon  reaction  mixture was performed  by 
37electroporation. Mutagenized fosmids were selected on LB agar plates supplemented 
with 100 µg/ml apramycin. Plates were incubated overnight at 37 °C and surviving 
colonies  were  randomly picked  and  grown  in  LB  liquid  culture  with  addition  of 
apramycin (185 µM). The mutagenized fosmid DNA from these colonies and control 
fosmid pXYF148 were digested with HindIII and analyzed by electrophoresis on 1% 
agarose  gels.  Colonies  carrying  mutagenized  fosmids  with  a  single  transposon 
insertion  were  randomly  selected  and  grown  in  liquid  culture  to  permit  fosmid 
isolation  and  identification  of  the  disrupted  gene.  Screening  was  conducted  by 
sequence analysis using the primer (5′- AAGGAGAAGAGCCTTCAGAAGGAA-3′). 
Fosmid pXYF148D3 was found to have Tn5AT inserted into the hpgT homolog region 
of orf29, at nucleotide position 41407 (GenBank Accession No. DQ403252).
Disruption of orf29 in S. fungicidicus ATCC21013
The  fosmid  pXYF148D3  was  then  introduced  into  wild-type  S.  fungicidicus  by 
intergeneric conjugation.14 Exconjugants surviving  apramycin selection were  passed 
through two rounds of sporulation without antibiotic selection to produce the stable 
disruptant  strain  via  double  crossover  homologous  recombination.  The  resulting 
spores were diluted and plated on ISP2 plate supplemented with apramycin (92 µM) to 
obtain single colonies, which were used to inoculate the TSB cultures for preparation 
of  the  genomic  DNA.  The  transposon  insertional  mutant  Sforf29::Tn5AT  was 
confirmed by Southern blot analysis of the chromosomal DNA and evidence of the 
abolishment of the enduracidin production in mycelia extracts. 
Southern blot analysis
Genomic  DNA from  wild  type  and  disruptant strains  was  prepared  as  described 
previously.3  Restricted  genomic  DNA  was  separated  by  electrophoresis  in  0.8% 
agarose  gel  and transferred  onto positively charged nylon membrane (Roche). The 
DNA probe  was prepared  using  digoxigenin-labeled  dUTP  and  hybridization  was 
revealed using a digoxigenin-DNA detection kit (Roche).
38Complementation and Fluorine Incorporation Studies
Seed cultures (S. fungicidicus or Sforf29::Tn5AT) were incubated in 4 mL TSB broth 
in 15 mL culture tube (VWR) shaking at a 70º angle, 200 rpm for 24 hrs at 28 ºC. 
Production  cultures  of  complex  media  (60  mL)  in  Erlenmeyer  flasks  (250  mL) 
equipped with a spring baffle were inoculated with 2 mL of seed culture. After shaking 
at 220 rpm at 28 ºC for 72 hrs. production cultures were supplemented with Hpg (24 
mg in 2 mL water), F-Tyr (48 mg in 3 mL water) or sustituted Hpg (48 mg in 3 mL 
water)  three  times  at  24  hrs  intervals.  All  supplementation  samples  required 
acidification with 0.1 N HCl to dissolve and were sterilized via syringe filtration (0.45 
µm, VWR). Cultures were harvested after 11 days.
HPLC and MS analysis
HPLC  analysis  was  performed  using  a  Shimadzu  (Kyoto,  Japan)  CBM-20A 
instrument equipped with an autosampler and a PDA detector scanning from 210 to 
330 nm. All samples were filtered through a 0.45 µm syringe filter prior to injection. 
Analysis was performed using a Phenomenex Gemini C18 column (4.6 × 150 mm, 5 
micron) with a 20 min. linear gradient from 10% acetonitrile in water with 0.1% TFA 
to 40% acetonitrile at a flow rate of 1.5 mL/min. Initial purification was performed 
using a Phenomenex Gemini C18 column (10 × 150 mm, 5 µm) with a 20 min. linear 
gradient from 10% acetonitrile in water with 0.1% TFA to 40% acetonitrile at a flow 
rate of 3 mL/min. Final  purification was performed using  a  Phenomenex  Polar-RP 
column (10 × 250 mm, 4 µm) with a linear gradient from 32% acetonitrile in water 
with  0.1%  TFA  to  40%  acetonitrile  over  17  min.  at 3  mL/min.  flow  rate.  Mass 
spectrometric  analysis was performed using  a  Waters/MicroMass LCT Classic  ESI 
spectrometer in positive ion mode, and a Thermo Finnigan LCQ Advantage instrument 
in ESI+ mode. 
NMR analysis and computational chemistry
39NMR  spectra  were  recorded  using  a  Bruker  300  MHz  instrument  for  synthetic 
compounds (1H-300 MHz,  13C-75 MHz). Proton NMR experiments on enduracidin 
were  performed  using  a  Bruker  Avance  III  700  MHz  instrument  (1H-700  MHz, 
13C-175 MHz). Enduracidin and fluorinated samples were dissolved in a mixture of 
2:5  D2O:Methanol-d4. The proton  shifts are  referenced  to methanol-d4 (3.31 ppm). 
Fluorine NMR spectra were recorded using a Bruker DPX-400 instrument (376 MHz) 
and a Bruker AvanceIII 500 instrument (471 MHz). Analysis of spectra was performed 
using Topspin ver. 1.3 and 3.1 (Bruker) and MestReNova ver. 8.0.2-11021 (Mestrelab 
Research). 
  Computational predictions and HOMO modeling was performed using Spartan 
10  ver.  1.0.1  (Wavefunction,  Inc.  Irvine,  CA  USA).  Charge  calculations  were 
performed using Marvinsketch ver. 5.10.3 (Chemaxon, Ltd. Cambridge, MA USA). 
  Amino acid sequence alignment and analysis was performed using Geneious Pro 
5.6.5 (Biomatters, Ltd. Auckland, NZ).
Bioactivity assay
A culture of S. aureus was grown over night at 37 °C on tryptic soy agar. A single pure 
colony was used to inoculate a 5 mL TSB culture which was shaken at 150 rpm for 4 
hrs at 37 °C. Antibiotic samples were prepared in 50% aq. MeOH and 20 µL of each 
dilution was loaded into wells on a 96-well Microtest plate (Falcon). To each test well 
was added 80 µL of sterile TSB followed by 100 µL of ~5 × 105 cells per mL of S. 
aureus  in  TSB.  Each  antibiotic  was  tested  concurrently  three  times  at  each 
concentration.  Initial  absorbance  readings at 600 nm  were  recorded and  the  plates 
were then sealed with parafilm and incubated at 37 °C for 16 hrs. Final absorbance 
readings were taken and percent growth calculated using the untreated well values as 
the reference. The percent inhibition was then calculated (100% – percent growth), the 
average was taken and standard deviations were calculated. MICs were determined as 
the lowest antibiotic concentration that exhibited >95% growth inhibition.
40Preparation of fluoro-hydroxyphenylglycines
Reagents were purchased from Sigma Aldrich or Alpha Aesar and used without further 
purification. Hydroxyphenolglycing  was purchased as ACS  grade in the  L form  at 
greater  than  98% purity. All  other  reagents were  purchased  as ACS  reagent grade 
products. Water was deionized (18 MΩ) using a Barnstead B-Pure filtration system. 
Acetonitrile  and  Methanol  were  purchased  as  HPLC  grade  solvents.  Anhydrous 
methanol was purchased and stored under Ar. Triethylamine was purchased as ACS 
reagent grade and passed through a column of basic alumina (50-200 µm) prior to use. 
Other solvents were purchased and used without further purification. 
N-benzyl-3-fluoro-4-methoxy-1-aminonitrile-benzene (4a): To a stirred solution of 
aldehyde 3a  (480  mg, 3.11  mmol) in acetonitrile (15 mL) was added benzylamine 
(410 µL, 3.7 mmol, 1.2 eq.), TMS-cyanide (400 µL, 3.11 mmol, 1 eq.) and cyanuric 
chloride (57 mg, 0.31 mmol, 0.1 eq.). The reaction was stirred for 5 hrs at ambient 
temperature and stopped by removing  the solvent under reduced pressure. The solid 
was dissolved in EtOAc (100 mL) and washed with water (50 mL) and brine (50 mL). 
The  organics  were  dried  over  anhydrous Na2SO4  and  the  solvent removed  under 
reduced pressure. The resulting  solid was purified using  flash chromatography SiO2 
1:3  EtOAc:Hexanes  yielding  4a  (650  mg,  2.4  mmol,  77%  yield)  as  a  yellow 
amorphous solid. 1H NMR (300 MHz, CDCl3) δ 7.63 – 7.10 (m, 7H), 6.97 (t, J = 8.6 
Hz, 1H), 4.69 (s, 1H), 4.18 – 3.61 (m, 5H), 1.86 (s, 1H); 13C NMR (75 MHz, CDCl3) δ 
152.40 (d, J = 247.6 Hz), 148.25 (d, J = 10.6 Hz), 138.00, 128.68, 128.39, 127.71, 
127.61, 127.53, 123.14, 123.09, 118.49, 115.43, 115.16, 113.45, 113.42, 56.33, 52.55, 
52.53, 51.14; LRMS ESI (+) m/z = 271.1 [M+H]+.
N-benzyl-2-fluoro-4-methoxy-1-aminonitrile-benzene  (4b):  Yield:  (772  mg,  3.24 
mmol, 88%) as yellow amorphous solid. 1H NMR (300 MHz, CDCl3) δ 7.55 – 7.18 
41(m, 5H), 7.17 – 7.03 (m, 2H), 6.67 (dd, J = 12.0, 2.5 Hz, 1H), 4.85 (bs, 1H), 4.81 (s, 
1H), 7.18, 4.00 (dd, J = 37.7, 14.0 Hz, 2H), 3.81 (s, 3H); 13C NMR (75 MHz, CDCl3) 
δ 161.73 (d, J = 11.2 Hz), 160.93 (d, J = 249.0 Hz), 139.09, 129.53 (d, J = 5.0 Hz), 
128.61, 128.38,  127.65, 118.30, 114.49 (d,  J  = 14.2  Hz), 110.28 (d, J  = 3.2  Hz), 
102.29 (d, J = 24.7 Hz), 55.72, 51.44, 47.53 (d, J = 3.0 Hz); LRMS, ESI (+) m/z = 
271.1 [M+H]+.
N-benzyl-2,6-difluoro-4-methoxy-1-aminonitrile-benzene  (4c):  Yield:  (965  mg, 
5.81 mmol, 58%) as yellow amorphous solid. 1H NMR (300 MHz, CDCl3) δ 7.54 – 
7.18 (m, 5H), 6.50 (dd, J = 9.7, 2.2 Hz, 2H), 5.67 (s, 1H), 4.87 (s, 1H), 4.15 – 3.88 (m, 
2H), 3.79 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 161.88 (dd, J = 14.3 Hz), 161.25 (dd, 
J = 248.5, 10.3 Hz), 137.49, 128.69, 128.42, 127.79, 117.58, 103.95 (dd, J = 18.6 Hz), 
98.55 (dd, J = 26.3, 2.8 Hz), 56.02, 51.67, 42.16 (dd, J = 4.0 Hz); LRMS, ESI (+) m/z 
= 289.1 [M+H]+.
N-benzyl-3-chloro-4-methoxy-1-aminonitrile-benzene (4d):  Yield:  (170  mg,  0.59 
mmol, 51%) white amorphous solid. 1H NMR (300 MHz, CDCl3) δ 7.55 (d, J = 2.4 
Hz, 1H), 7.49 – 7.22 (m, 6H), 6.93 (d, J = 8.5 Hz, 1H), 4.67 (s, 1H), 4.11 – 3.78 (m, 
5H), 1.87 (s, 1H);  13C  NMR (75  MHz,  CDCl3) δ 155.47, 138.00, 129.18,  128.66, 
128.38, 127.80, 127.68, 126.70, 122.98, 118.49, 112.10, 56.25, 52.42, 51.14; LRMS, 
ESI (+) m/z = 287.1.
N-benzyl-3-fluoro-4-methoxy-phenylglycine (5a):  A solution  of  90%  formic  acid 
(410 µL, 9.8 mmol, 9.5 eq) and acetic  anhydride  (950 µL, 9.8 mmol, 9.5 eq) was 
stirred at 60 °C for 1 hr. The resultant solution of acetic-formic mixed anhydride was 
cooled in an ice bath and added to a cooled flask of aminonitrile  4a (280 mg, 1.0 
mmol). The reaction was stirred at 0 °C for 15 min. then at ambient temperature for 1 
hr. To the reaction was added, slowly, concentrated HCl (2.5 mL). The reaction was 
42heated at 65 °C for 2 hrs then refluxed for 1 hr. The reaction was then allowed to cool 
and the solvent was removed under reduced pressure. The solid was triturated with 
DCM and the insolubles were collected by filtration as a white powder. The product 
was used in the next reaction without further purification. LRMS, ESI (+) m/z 290.1 
[M+H]+.
N-benzyl-2-fluoro-4-methoxy-phenylglycine (5b): Grey powder; LRMS, ESI (+) m/
z = 290.1.
N-benzyl-2,6-difluoro-4-methoxy-phenylglycine (5c): Grey powder; LRMS, ESI (+) 
m/z = 308.1.
N-benzyl-3-chloro-4-methoxy-phenylglycine (5d): Grey powder; LRMS, ESI (+) m/
z = 306.1.
N-benzyl-3-fluoro-4-hydroxy-phenylglycine (6a): To a flask containing N-benzyl-3-
fluoro-4-methoxy-phenylglycine  5a  (250  mg)  was  added  conc.  HBr  (9  mL).  The 
solution was refluxed for 3 hrs. The solvent was removed under reduced pressure. The 
solid product was dissolved in minimal 0.1 N HCl and the product was precipitated by 
adjusting  the pH to 6.5 with 0.1 N NaOH. The  solid was washed with MeOH and 
dried in vacuo yielding a white powder (200 mg, 0.73 mmol, 73% yield from 4a). 1H 
NMR (300 MHz, DMSO) δ 10.15 (bs, 1H), 8.90 (t, J = 13.6 Hz, 1H),7.81 – 6.80 (m, 
8H), 4.98 (m, 1H), 3.97 (dd, J = 51.8, 12.7 Hz, 2H);  13C NMR (75 MHz, DMSO) δ 
170.00, 151.09 (d, J = 242.3 Hz), 151.01 (d, J = 241.9 Hz), 146.86 (d, J = 11.7 Hz), 
146.38 (d,  J = 11.0 Hz),  131.87, 130.81, 129.43,  128.93, 126.34 (d,  J = 3.0  Hz), 
125.20 (d, J = 2.8 Hz), 118.56 (d, J = 2.7 Hz), 118.40 (d, J = 3.1 Hz), 117.32 (d, J = 
19.5 Hz), 116.57 (d, J = 19.7 Hz), 55.01, 49.21. LRMS, ESI (+) m/z = 276.1 [M+H]+.
43N-benzyl-2-fluoro-4-hydroxy-phenylglycine (6b): Yield: (450 mg, 1.7 mmol, 57% 
yield from 4b). 1H NMR (300 MHz, D2O) δ 7.57 – 7.49 (m, 3H), 7.49 – 7.44 (m, 2H), 
7.37 – 7.31 (m, 1H), 6.88 – 6.79 (m, 2H), 5.21 (d, J = 1.1 Hz, 1H), 4.40 – 4.20 (m, 
2H); 13C NMR (75 MHz, D2O) δ 170.24, 161.45 (d, J = 247.1 Hz), 159.48 (d, J = 11.9 
Hz), 131.43 (d, J = 4.6 Hz), 130.09, 129.89, 129.69, 129.20, 112.60, 109.16 (d, J = 
14.8 Hz), 103.61 (d, J = 24.2 Hz), 57.19, 49.73. LRMS, ESI (+) m/z = 276.1 [M+H]+.
N-benzyl-2,6-difluoro-4-hydroxy-phenylglycine (6c): The difluoro compound could 
not be purified by the above method. Completion of the reaction was confirmed by 
LRMS with the appearance of ESI (+) m/z = 294.1 [M+H]+ and disappearance of the 
m/z = 308.1 ion. The crude product was taken on to the next reaction. 
N-benzyl-3-chloro-4-hydroxy-phenylglycine (6d): Yield: (103 mg, 0.35 mmol, 59% 
yield from 4d). 1H NMR (300 MHz, DMSO-d6) δ 10.86 (bs, 1H), 7.57 (d, J = 2.0 Hz, 
1H), 7.54 – 7.36 (m, 6H), 7.33 (dd, J = 8.6, 2.1 Hz, 1H), 7.14 (d, J = 8.3 Hz, 1H), 5.00 
(s, 1H), 4.36 – 3.67 (m, 2H); 13C NMR (75 MHz, DMSO) δ 168.79, 154.45, 131.42, 
130.51, 130.29, 128.99, 128.93, 128.45, 122.33, 119.90, 116.94, 61.28, 48.95; LRMS, 
ESI (+) m/z = 292.1 [M+H]+.
3-fluoro-4-hydroxy-phenylglycine  (7a):  To  a  flask  containing  N-benzyl-3-F-4-
hydroxyphenylglycine 6a (200 mg, 0.73 mmol) dissolved in water (2 mL) and acetic 
acid (4 mL) was added Pd/C (15 mg, 0.01 mmol, 0.01 eq). The flask was flushed with 
H2 three times and stirred overnight at ambient temperature. The reaction mixture was 
filtered through celite. The solvent of the collected filtrate was removed under reduced 
pressure. The crude product was crystallized from water heated and pH adjusted to 6.5 
yielding 7a as grey plates (75 mg,  71 mmol, 56% yield). 1H NMR (300 MHz, D2O) δ 
7.48 – 7.36 (m, 1H), 7.29 (d, J = 2.0 Hz, 1H), 7.25 (d, J = 8.4 Hz, 1H), 5.22 (s, 1H); 
13C NMR (75 MHz, D2O) δ 171.07, 151.42 (d, J = 242.0 Hz), 145.11 (d, J = 12.7 Hz), 
44125.07 (d, J = 3.4 Hz), 124.29, 124.21, 118.78 (d, J = 3.0 Hz), 116.28 (d, J = 20.0 Hz), 
56.18; LRMS, ESI (+) m/z = 186.0 [M+H]+.
2-fluoro-4-hydroxy-phenylglycine (7b): Yield: (200 mg, 1.1 mmol, 62%). 1H NMR 
(300 MHz, D2O) δ 7.32 (t, J = 8.8 Hz, 1H), 6.95 – 6.57 (m, 2H), 5.27 (s, 1H); 13C 
NMR (75 MHz, D2O) δ 170.73, 161.18 (d, J = 246.7 Hz), 159.17 (d, J = 12.2 Hz), 
131.22 (d, J = 4.7 Hz), 112.41 (d, J = 2.9 Hz), 110.57 (d, J = 14.8 Hz), 103.57 (d, J = 
23.9 Hz), 51.06 (d, J = 2.5 Hz); LRMS, EST (+) m/z = 186.0 [M+H]+.
2,6-difluoro-4-hydroxy-phenylglycine (7c): Yield: (427  mg, 2.1  mmol, 36% from 
6c). 1H NMR (300 MHz, D2O) δ 6.25 (d, J = 10.9 Hz, 2H), 5.12 (s, 1H); 13C NMR (75 
MHz, D2O) δ 169.52, 161.17 (dd, J = 247.5, 10.2 Hz), 159.85 (dd, J = 15.2 Hz), 99.83 
(dd, J = 25.1, 2.4 Hz), 99.26 (dd, J = 19.0 Hz), 45.67; LRMS, ESI (+) m/z = 204.0 [M
+H]+.
3-chloro-4-hydroxy-phenylglycine  (7d):  The  reaction  was  not  successful.  The 
reducing conditions caused the removal of the chlorine group and Hpg  was the only 
observed product.
N-Trifluoroacetyl-4-hydroxy-phenylglycine-methyl ester  (9): To  a  solution of  L-
Hpg 8 (3.0 g, 18 mmol) in anhydrous MeOH (150 mL) under Ar and cooled in an ice 
bath was added thionyl chloride (2.61 mL, 36 mmol, 2 eq.) over 20 min. The reaction 
was  then  refluxed  overnight.  The  reaction  was  allowed  to  cool  and  the  solvent 
removed in vacuo. The crude product was then cooled in an ice bath and treated with 
trifluoroacetic anhydride (15.1 mL, 110 mmol, 6 eq) and allowed to warm to ambient 
temperature. After stirring for 3 hrs the reaction was diluted with EtOAc (100 mL) and 
quenched with saturated  NaHCO3 (500  mL). The organic layer  was separated and 
dried with Na2SO4 then removed in vacuo yielding 9 as a white amorphous solid (4.98 
45g, 18.0 mmol, quantitative). 1H NMR (300 MHz, CDCl3) δ 7.34 (d, J = 7.0 Hz, 1H), 
7.22 (d, J = 8.6 Hz, 2H), 6.81 (d, J = 8.6 Hz, 2H), 5.48 (d, J = 6.9 Hz, 1H), 5.20 (s, 
1H), 3.78 (s, 3H);  13C NMR (75 MHz, CDCl3) δ 170.35, 156.68 (q, J = 38.5 Hz), 
156.35, 128.90, 126.86, 116.25, 118.36-112.41 (m), 56.17, 53.51; LRMS, ESI (-) m/z 
= 276.0 [M-H]-. 
N-Trifluoroacetyl-3-nitro-4-hydroxy-phenylglycine-methyl ester (10): To a stirred 
solution of 9 (1.0 g, 3.6 mmol) in AcOH (100 mL) under Ar was added NaNO2 (500 
mg, 7.22 mmol, 2 eq.). The reaction stirred for 3 hrs. The solvent was removed under 
reduced  pressure  and the  crude  product was  dissolved in MeOH and purified  via 
HPLC; Phenomenex  Polar RP column (10 x  250mm, 4 µm) 20 min. gradient from 
10% to 70% MeOH in water with a flow rate of 3 mL/min. yielding  10 as a white 
amorphous solid (812 mg, 2.5 mmol, 70%). 1H NMR (300 MHz, CDCl3) δ 10.61 (s, 
1H), 8.12 (d, J = 1.8 Hz, 1H), 7.59 (dd, J = 8.8, 2.3 Hz, 1H), 7.55 (bs, 1H), 7.21 (d, J = 
8.7 Hz, 1H), 5.52 (d, J = 6.5 Hz, 1H), 3.81 (s, 3H); 13C NMR (75 MHz, CDCl3)  δ 
169.40,  156.72  (q, J  = 38.5  Hz), 155.54,  136.20, 133.69,  127.34, 124.07,  121.31, 
118.05 – 113.29 (m), 55.59, 53.93; LRMS, ESI (-) m/z = 321.0 [M-H]-.
3-nitro-4-hydroxy-phenylglycine (11): A solution of 10 (500 mg, 1.6 mmol) in 6 N 
hydrochloric acid was refluxed under Ar for 18 hrs. The reaction was cooled and the 
solvent removed in vacuo. The resulting white powder (310 mg, 1.2 mmol, 80% yield 
as  HCl  salt)  was  shown  to  be  pure  via  HPLC  and  was  used  without  further 
purification. 1H NMR (300 MHz, DMSO-d6) δ 8.05 (s, 1H), 7.62 (d, J = 8.2 Hz, 1H), 
7.28 (d, J = 8.4 Hz, 1H), 4.99 (s, 1H); 13C NMR (75 MHz, DMSO) δ 169.09, 152.52, 
136.50, 134.80, 125.03, 124.80, 119.41, 54.63, 39.52; LRMS, ESI (+) m/z = 213.0.
5-Benzyloxy-2-methyl-pyridine (13): To a suspension of NaH (2.0 g, 50 mmol) in 
distilled THF (100 mL) cooled in an ice bath was added 5-hydroxy-2-methylpyridine   
4612 (5.0 g, 46 mmol) dissolved in anhydrous DMF (50 mL) and stirred for 30 min. To 
the mixture was added benzylbromide (6.1 mL, 50 mmol) after which the reaction was 
removed from cooling and stirred at ambient temperature for 18 hrs. The reaction was 
quenched with saturated NaHCO3 and extracted 3 times with EtOAc. The combined 
organics were washed with water and brine then dried over Na2SO4. The solvent was 
removed in vacuo. The crude product was purified via silica gel flash chromatography 
eluting  with 1:2 EtOAc–hexanes affording  the pure compound 13 (6.5 g, 33 mmol, 
71% yield). 1H NMR (300 MHz, CDCl3) δ 8.27 (d, J = 3.0 Hz, 1H), 7.48 – 7.29 (m, 
5H), 7.15 (dd, J = 8.5, 3.0 Hz, 1H), 7.04 (d, J = 8.5 Hz, 1H), 5.07 (s, 2H), 2.48 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 152.99, 150.78, 137.24, 136.51, 128.74, 128.27, 127.58, 
123.38, 122.54, 70.58, 23.48; LRMS, ESI (+) m/z = 200.1.
5-Benzyloxy-2-acetatoxymethyl-pyridine (15):  To a  solution of protected methyl-
pyridine 13 (700 mg, 3.5 mmol) in CHCl3 (20 mL) cooled in an ice bath was added 
mCPBA (890 mg, 3.9 mmol) and stirred for 1 hr. The reaction was quenched with 5% 
aqueous Na2CO3 and extracted with EtOAc. The organics were washed with brine and 
dried over  Na2SO4. The  solvent was removed under  reduced pressure yielding  the 
crude  N-oxide  14.  The  crude  product  was  then  added  to  heated  (80  ºC)  acetic 
anhydride (11.4 mL, 71 mmol) and then stirred at 130 ºC for 30 min. The reaction was 
then poured into ice water (20 mL) and stirred for 2 hrs. The mixture was extracted 
with EtOAc. The extract was washed with saturated NaHCO3, brine and then dried 
over Na2SO4. The  solvent was removed in vacuo and the compound purified using 
silca  gel  flash  chromatography (1:2  EtOAc–Hexanes)  affording  15  (730  mg,  2.8 
mmol, 80% yield) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 8.36 (d, J = 2.5 Hz, 
1H), 7.46 – 7.14 (m, 8H), 5.15 (s, 2H), 5.11 (s, 2H), 2.12 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 170.85, 154.55,  147.99,  138.17, 136.13, 128.85, 128.45,  127.60,  123.14, 
122.16, 70.61, 66.83, 21.07; LRMS, ESI (+) m/z = 257.1.
475-Benzyloxy-2-formyl-pyridine (16):  To  a  solution of  15 (720  mg, 2.8  mmol) in 
ethanol (7 mL) was added 1 N NaOH (1.8 mL). The solution was refluxed for 1.5 hrs 
then  allowed  to  cool  and  concentrated.  The  aqueous  residue  was  extracted  with 
CHCl3. The extract was washed with water and dried over Na2SO4. The organics were 
then removed and the residue precipitated from EtOAc–Hexanes. The crude alcohol 
was dried under high vacuum overnight. The alcohol was dissolved in CHCl3 (17 mL) 
and MnO2 (1.7 g, 19.5 mmol) was added and the mixture was refluxed for 30 min. The 
reaction mixture was filtered through celite  and the solvent removed under reduced 
pressure. The crude product was purified using  silica gel flash chromatography (1:4 
EtOAc–Hexanes)  to  yield  aldehyde  16  (320  mg,  1.5  mmol,  52%  yield)  as  white 
crystals. 1H NMR (300 MHz, CDCl3) δ 9.92 (s, 1H), 8.43 (d, J = 2.8 Hz, 1H), 7.85 (d, 
J = 8.6 Hz, 1H), 7.42 – 7.22 (m, 6H), 5.11 (s, 2H);  13C NMR (75 MHz, CDCl3) δ 
191.72,  157.94,  146.27,  138.93,  135.09,  128.67,  128.44,  127.40,  123.15,  120.81, 
70.49; LRMS, ESI (+) m/z = 214.1.
5-Benzyloxy-2-(N-Bn-NAc-aminonitrile)-pyridine (17): To a solution of aldehyde 
16 (100 mg, 0.47 mmol) and benzylamine (51 µL, 0.47 mmol) in THF (0.5 mL) under 
Ar was added ZnI2 (74 mg, 0.23 mmol). The reaction was stirred for 10 min. then 
TMS- cyanide (66 µL, 0.52 mmol) was added. The reaction was stirred for 1 hr then 
cooled and acetic anhydride  (180 µL, 1.7 mmol) and pyridine (190 µL, 2.3 mmol) 
were added. The reaction was allowed to come to ambient temperature over 2 hrs. The 
reaction was poured into water and extracted with EtOAc. The organics were washed 
with  saturated  NaHCO3,  water,  brine  and  dried  over  Na2SO4.  The  solvent  was 
removed under reduced pressure and the crude product was purified via silica gel flash 
chromatography (1:4 EtOAc–hexanes) yielding  aminonitrile 17 (50 mg, 0.13 mmol, 
28% yield) as colorless amorphous solid. 1H NMR (300 MHz, CDCl3) δ 8.37 (d, J = 
2.9 Hz, 1H), 7.48 – 7.22 (m, 12H), 5.12 (s, 2H), 4.75 (s, 1H), 4.25 – 3.88 (m, 2H), 
2.04 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 171.23, 154.87, 143.81, 138.09, 135.86, 
48135.55,  128.60,  128.55,  128.27,  127.37,  127.32,  126.03,  123.38,  122.06,  116.36, 
70.30, 60.18, 50.22, 21.68; LRMS, ESI (+) m/z = 372.5.
5-Benzyloxy-2-(N-Bn-methylamine)-pyridine  (20):  Aminonitrile  17  (13  mg,  35 
µmol) was dissovled in anydrous MeOH (500 µL) at 0 ºC and treated with 3 M HCl in 
MeOH (200  µL). The  reaction  was stirred  for  three  hrs.  and  allowed  to  come  to 
ambient temperature over four hrs. The solvent was removed under reduced pressure 
and the product was dissolved in EtOH (2 mL) and Pd/C (2 mg, 0.8 µmol) was added 
and stirred under H2 atmosphere for 4 hrs. The reaction was filtered through celite and 
the solvent removed. NMR and MS results indicated a decarboxylation reaction or loss 
of cyanide had occured producing amine 19 instead of hydroxypyridinylglycate 18. 1H 
NMR (300 MHz, D2O) δ 7.85 (d, J = 2.6 Hz, 1H), 7.72 – 7.38 (m, 2H), 7.12 – 
6.78 (m, 5H), 4.15 (s, 2H), 3.90 (s, 2H);  13C NMR (75 MHz, D2O) δ 156.21, 
134.47, 133.10, 130.71, 129.80, 129.73, 129.61, 129.36, 129.03, 51.27, 45.58; 
LRMS ESI (+) m/z = 215.1.
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52CHAPTER THREE
BIOSYNTHESIS OF ENDURACIDIDINE
Neal GoebelIntroduction
  Enduracidin contains 17 amino acid residues. Four are proteinogenic residues 
and  13 are  nonproteinogenic, with seven having  the  D configuration.  One  of these 
residues, enduracididine (End), found in both the D and L configurations, contains a 2-
amino-2-imidazoline  moiety;  an  uncommon  amino  acid  structure  (Fig.  3.1). 
Structurally similar amino acids include: capreomycidine and viomycidine from the 
tuberactinomycins1 ( i n c l u d i n g  v i o m y c i n 2 a n d  c a p r e o m y c i n ) ,  m u r a y m y c i n 3  and 
chymostatin4;  stendomycidine  from  stendomycin5;  3-hydroxyenduracididine  from 
mannopeptimycin6; and tetrahydrolathyrine7 a derivative of lathyrine.8 Enduracididine 
and  N-(6-bromo-1H-indolyl-3-carbonyl)-L-enduracididine  were  isolated  from  the 
ascidian Leptoclinides dubius.9 The seeds from Lonchocarpus sericeus were found to 
contain  enduracididine  as  well.10  The  aminocyclitol  minosaminomycin  is  the  only 
other  structurally  complex  bioactive  natural  product  reported  that  contains 
enduracididine.11 While the aminoimidazoline structure is found in a variety of natural 
products  with  deduced  biosynthetic  pathways,  the  mechanism  of  enduracididine 
biosynthesis remains unknown.12
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Figure 3.1 The structure of enduracidin with amino acid labels.  Initial  studies  into  the  biosynthetic  origin  of  enduracidin  found  through  14C 
radiolabeling  studies that enduracididine was likely produced from arginine (Arg).13 
Work on the capreomycidine biosynthetic pathway found that a hydroxyl group was 
introduced on the 3-carbon of Arg by the 2-ketoglutarate-dependent monooxygenase 
VioC.14 The resulting 3-hydroxy-Arg (3-OH-Arg) was cyclized using an elimination-
cyclization  reaction  catalyzed  by  the  PLP-dependent  enzyme  VioD  (Fig.  3.3).15 
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Figure 3.2 Natural products containing enduracididine and similar amino acid structures. 
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MinosaminomycinBioinformatic analysis of the enduracidin biosynthetic pathway identified three open 
reading  frames  (orfs)  that  were  postulated  to  be  involved  in  enduracididine 
biosynthesis:  endP,  endQ a n d  endR.16  Comparison  to  the  mannopeptimycin 
biosynthetic  pathway revealed  a  highly similar  operon  containg  four  orfs:  mppO, 
mppP, mppQ and mppR.17 A series of experiments involving  recombinant MppO, an 
oxygenase similar to VioC, indicated that it was responsible for the introduction of the 
3-hydroxyl  group on  End and did not accept Arg  as a substrate.18 End  is the only 
unusual amino acid common between the two peptides and as endPQR and mppPQR 
share  high  sequence  similarity,  the  gene  products  are  likely  responsible  for  End 
biosynthesis.  Bioinformatic  analysis  classified  the  gene  products into  two  groups: 
EndP and EndQ are predicted to be PLP-dependent enzymes, while EndR is loosely 
related to the acetoacetate  decarboxylase (ADC) family of enzymes.16 Interestingly, 
none of the enzymes shared similarity with an oxygenase enzyme. 
  The presence of the PLP-dependent enzyme suggests an elimination–cyclization 
reaction is used in the formation of enduracididine. These types of reactions require 
the introduction of a leaving group, often a hydroxyl group, which then is eliminated 
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Figure  3.3  Biosynthesis  of  3-S-L-capreomycidine  via  non-heme  iron  α-ketoglutarate 
dependent  oxygenase VioC  and the pyridoxal phosphate dependent  enzyme VioD from L-
arginine.via conjugation to the PLP cofactor. Mechanisms involving  either a 3-OH or 4-OH 
Arg as a precursor are possible (Fig. 3.4). Michael-type reactions have been shown to 
be  involved  in  the  formation  of  naturally  occurring  aminoimidazolines.  The 
guanidinomines, noted for  their  inhibition  of type III  secretion, contain a  terminal 
aminoimidazoline ring originating from guanidinoacetate. After formation of the PKS-
bound  4-guanidino-but(2-ene)oate  intermediate  the  guanidine  cyclizes  onto  C3 
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Figure 3.4 Possible mechanisms  for a pyridoxal phosphate catalyzed elimination cyclization 
reaction producing L-enduracididine from A) 3-OH arginine and B) 4-OH arginine.forming  the  aminoimidazoline  moeity.19  A  series  of  three  similar  Michael-type 
reactions  are  involved  in  the  biosynthesis  of  the  cyanobacterial  cytotoxin 
cylindrospermopsin suggesting the formation of the aminoimidazoline ring of End by 
Michael-type reaction is probable.12b
  The function of EndR is unknown. As no other enzymes are predicted to have 
oxidative/hydroxylation activity, EndR may be an unknown form of a hydroxylase. 
The ADC family of enzymes utilize a Lys residue to form an imine with 3-keto acids 
and catalyze the decarboxylation reaction, as illustrated by the ADC from Clostridum 
acetobutylicum  (Fig.  3.5).20  Given  the  limited  bioinformatic  data  on  the  enzyme 
experimentation is the  only means to gain further understanding  of its role in End 
biosynthesis.
 P r e v i o u s   w o r k   o n   t h i s   b i o s y n t h e t i c   p r o b l e m   h a d   f o c u s e d   a r o u n d   t h e  
overexpression and isolation of the proteins EndP EndQ and EndR for in vitro testing 
of the proposed biosynthetic intermediates Arg, 3-OH Arg and 4-OH Arg and possible 
cofactors. Though significant work  was performed,  poor solubility of  the  proteins 
proved  an  insurmountable  obstacle.  To  overcome  this  limitation,  in  vivo 
complementation experiments were approached. As the work moved forward on the 
complementation experiments we began a collaboration  with Dr. Nicholas Silvaggi 
(University of Wisconsin-Milwaukee), a structural biologist. Dr. Silvaggi’s work has 
focused on the mannopeptimycin biosynthetic proteins MppP, MppQ and MppR. From 
these  two  complementary  approaches  important  details  have  been  uncovered 
concerning the biosynthesis of enduracididine.
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Figure  3.5  Mechanism  of  action  of  acetoacetate  decarboxylase  from  Clostridium 
acetobutylicum. Results and Discussion
  To  perform  the  complementation  studies,  the  preparation  of  biosynthetic 
intermediates as well as enduracididine was undertaken. Previous work with the Gould 
lab provided a source of L-3-OH arginine in both L-3-R and L-3-S configurations.15, 21 
Additionally, a method for preparing 4-OH Arg had previously been accomplished in 
our lab (Fig  3.6). Briefly, Boc protected allyl-glycine (1) is subjected to an iodine-
mediated cyclization reaction under basic conditions. The resulting iodo-lactones (2 
and 3) are converted to the azide (4) and subsequently reduced to the amine (5). The 
amine  is  then  converted  to  the  diBoc-protected  guanidine  (6)  using  Mukaiyama’s 
reagent (8)  and N,N’-diBoc thiourea.22 The  lactone  is then  hydrolyzed  under basic 
conditions and the Boc groups are removed under acidic conditions, yielding 4-OH 
Arg (7).23
  Though reported to give  high yields and being  used in many examples in the 
literature,  the  use  of Mukaiyama’s reagent for  the  guanylating  reaction gave  poor 
yields and side products proved difficult to separate.24 Other reactions involving Hg 
catalysts had proved to be  unsuccessful in the past work on this reaction.23, 25 The 
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Figure 3.6 Synthesis of 4-OH Arg from allylglycine via iodine-mediated lactonization and using 
Mukaiyama’s reagent and diBoc-thiourea for the guanylation reaction.larger  scale  production  of  4-OH  Arg  called  for  a  new  guanylating  reagent. 
Additionally,  a  reaction  where  exposure  of  the  lactone  to  the  free  amine  (5)  was 
limited, preventing lactam formation or polymerization, was desirable. The work by 
Goodman et al. appeared to provide  a viable  solution to  the problem.26 The  N-Tf-
N’,N”-diBoc-guanidine (Tf-guan) (11) reagent is readily produced in good yields from 
guanidine   (9) on a large scale (Fig. 3.7A). The product is stable and proved to be 
highly effective in the production of 4-OH Arg. The yields were increased from ~20% 
with  difficult  isolation  using  Mukaiyama’s  reagent  to  84%  of  readily  purified 
compound using Tf-guan (Figure 3.7B). The reaction could also run under reducing 
conditions,  allowing  the  combination  of  the  azide  reduction  and  the  guanylation 
reaction in a one pot reaction. The increased yield, facile isolation, one-pot reaction 
setup and the ability to run gram-scale reactions made Tf-guan an ideal reagent for 
preparing 4-OH Arg. 
  The  ability to  selectively produce  single  diastereomers of  4-OH Arg  was  of 
interest.  Crystallization  of  the  crude  iodolactone  product  from  EtOAc–Hexanes 
selectively yielded the cis product (Fig 3.8A and B). The initial complementation work   
primarily aimed to utilize a racemic mixture of the four diastereomers of 4-OH Arg for 
testing. Further investigation would require the production of single diastereomers. To 
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Figure 3.7 A) Preparation of the Tf-guan reagent from guanidine. B) Preparation of 4-OH Arg 
from the azidolactone 4 using the Tf-guan reagent.  
A
Bproduce the 4-S isomer, L-allylglycine was selected as the starting material. Successful 
production of 4-S-OH-L-Arg  was observed in the  1H NMR spectra of racemic and 
enriched  guanidinyl-lactone  (6)  (Fig.  3.8  C  and  D). Attempts to  isolate  the  trans 
configured iodolactone through repeated crystallization proved unsuccessful. 
  Large  quantities of End were needed to establish a complementation protocol, 
demonstrate the ability to chemically complement endPQR mutant strains and serve as 
a  positive  control  during  the experiments. Previous preparations of End have  been 
accomplished.27 Recently work by Dodd’s group produced protected enduracididine in 
a stereo specific manner. Unfortunately, the methodology involved several low yield 
conversions and required HPLC purification for several steps. The strategy devised by 
Tsuji  et  al. appeared  to be promising, however  the experience of others in the lab 
indicated the process was unreliable and gave yields too low to be practical for the 
supplementation experiments. 
  In evaluating the preparation of End from His, several examples were found for 
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Figure  3.8  1H-NMR  spectra  of  A)  a  mixture  of  cis a n d  trans  iodolactones  2 a n d 3,  B) 
crystallized cis  iodolactone 2,  C)  a  mixture  of cis  and  trans  guanidinyl-lactone 7 and D) 
purified guanidinyl-lactone 6 having an absolute configuration of 2-S, 4-S. 
A
B
C
D
H5
NH
O
O
Boc
R
H3R
H3S
H2
H4
Η5
Η5
NH
O
O
Boc
R
H3R
H3S
Η2
H4
Η5
Η5
c-H3S
c-H3S t-H3R
c-H3R
c-H3R
H4
H4
c-H3S
c-H3S
c-H3R
c-H3R
t-H3R
t-H3Sgenerating  2,4,5-triamidopent(4-ene)oate  from  L-His  (a  Bamberger  cleavage), 
including industrial applications.27b, 28 The reduction of the  diamido-alkene had been 
previously demonstrated by Altman et al. and could be circumvented via hydrolysis of 
one enamide to form the ketone.28b The triamine could easily be produced via acidic 
hydrolysis. The selective formation of cyclic guanidine between vicinal amines in the 
presence  of  other  amines  had  been  previously accomplished  in  the  synthesis  of 
streptolidine by utilizing cyanogen bromide under basic conditions.29 Requiring only 4 
steps  from  readily available  L-His methyl  ester and just one  chromatography step 
during  preparation,  this  synthetic  route  was  chosen  for investigation  before  other, 
more complex, routes were explored. 
  The imidazole ring  of His was successfully opened using Bamberger cleavage 
conditions affording the 2,4,5 N-benzamido-pent-4-eneoate methylester (13) in good 
yield  (Fig.  3.9).  The  reduction  of  (13)  to  produce  the  unsaturated  product 
triamidopentanoate (14) required acidic conditions and heating, but proved a viable 
method.  Acidic  hydrolysis  of  the  benzoyl  groups  with  6  N  HCl  yielded  the 
triaminopentanoic  acid  (15).  The  introduction  of  the  amino-imidazoline  ring  was 
accomplished  using  cyanogen  bromide.  When  pH  was  controlled  using  tribasic 
sodium  phosphate  buffer  the  yields  were  significantly lower,  ~30%  yield.  It was 
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Figure 3.9 The preparation of enduracididine from the methyl ester of L-histidine.observed that the buffer was insufficient to maintain the pH above 10 for the duration 
of the reaction. Alternately, continuous monitoring of the reaction pH and adjustment 
using 1 N NaOH to maintain ~ pH 10.5 over the duration of the reaction resulted in a 
significant increase in yield (72%) over 2 steps starting from 6 g of triamide (14). The 
product was easily isolated via ion exchange chromatography. This short preparation 
of enduracididine afforded large quantities with an efficiency not previously reported.
  NMR  analysis  of  the  product  showed  a  doubling  of  the  13C  NMR  signals 
suggesting  that both diastereomers were formed (Fig. 3.10). The C2 and C1 signals 
were shifted by 21.4 and 11.3 Hz respectively. The greatest signal shift observed was 
for C3 at 23.6 Hz. The resonances of C4 and C5, being in the rigid aminoimidazoline 
ring showed the smallest signal shifts at 9.8 and 13.7 Hz respectively. The shifts may 
result from rigid structures formed due to intramolecular hydrogen bonding unique for 
each of the diastereomers produced. HMBC experiments showed no correlations from 
the C2 and C3 protons to the guanidinyl carbon. The results support the assignment of 
the ring structure as that of End. 
  For the complementation studies, a series of genetic mutations were introduced 
by Dr. Yin, disrupting endP, endQ and endR using methods previously described.16, 30 
An  in-frame  deletion  was  used  to  remove  endP  from  the  wild-type  strain  of  S. 
Fungicidicus,  creating  the  strain  denoted  SfΔendP.  Strains  with  endQ  and  endR 
disrupted via  insertion of the  apramycin resistance gene aac(3)IV were  denoted  as 
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Figure 3.10 13C NMR (75 MHz, D2O) of synthetic enduracididine (16) showing the doubling of 
signals.64
Figure 3.11 Diagram showing the disruptions  introduced into endP, endR and endQ of S. 
fungicidicus.
Figure 3.12 HPLC chromatograms  of mycelial extracts of A) SfendRΩAmR  + 3-S-OH Arg, B) 
SfendRΩAmR + 3-R-OH Arg, C) SfendRΩAmR, D) SfΔendP + 3-S-OH Arg, E) SfΔendP + 3-R-
OH Arg, F) SfΔendP and G) S. fungicidicus wild type. Enduracidin is indicated with asterisks. 
The peak marked with an X was determined not to be enduracidin from UV data.
A
B
C
D
E
F
G
X
* *SfendRΩAmR and SfendQΩAmR respectively (Fig. 3.11). The genetic modifications 
were  confirmed  by Southern  blot  hybridization.  The  resulting  mutants  were  then 
screened for enduracidin production. Each showed an inability to produce enduracidin. 
Each of the  mutants was then supplemented with 3-S-OH-L-Arg, 3-R-OH-L-Arg  or 
racemic 4-OH Arg. A culture  of  each group was also supplemented with synthetic 
enduracididine to serve as a control (data not shown for all experiments). The results 
for  the  3-OH  Arg  experiments  indicated  that  supplementation  failed  to  restore 
enduracidin  production  in  any  of  the  mutant  strains  (Fig.  3.12).  Only  the 
SfendQΩAmR strain was not complemented by the addition of enduracididine  (Fig. 
3.13). In the 4-OH Arg experiments, both the SfΔendP and SfendRΩAmR strains were 
complemented  and  enduracidin  production  was restored. This  complementation  of 
both the endP and endR mutants suggested that EndP and EndR were responsible for 
the  production  of  4-OH  Arg.  To  further  test  this  result,  4-S-OH-L-Arg  was 
supplemented to cultures of the SfΔendP and SfendRΩAmR strains. The results again 
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Figure 3.14 HPLC chromatograms of mycelial extracts of IA) SfendRΩAmR, IB) SfendRΩAmR 
+  4-OH  Arg,  IC)  SfendRΩAmR  +  End,  ID)  S.  fungicidicus  wild  type,  IIA)  SfΔendP,  IIB) 
SfΔendP + 4-OH Arg, IIC) SfΔendP + End and IID) S. fungicidicus wild type. Enduracidin is 
indicated with asterisks. showed  the  restoration  of  enduracidin  production  (Fig.  3.14).  The  production  of 
enduracidin was confirmed by LCMS  which  showed  masses  at m/z = 1177.2 and 
1184.3 Da, corresponding with [M+2H]2+ for enduracidins A and B respectively.
  The complementation results led to a hypothetical biosynthetic route where EndP 
and  EndR  are  responsible  for  the  production  of  4-OH Arginine  or  2-keto-4-OH 
arginate  and  EndQ  is  responsible  for  the  cyclization  reaction  and  releasing 
enduracididine. Using  the bioinformatic  data  as a  guide, EndP would function as a 
transaminase  forming  2-keto-arginate  which  is  then  oxidized  by EndR to  yield  2-
keto-4-OH arginate. This species could then be transformed to 4-OH Arg by EndP or 
used directly by EndQ. EndQ could theoretically cyclize either product, only requiring 
a change from pyridoxal  phosphate to pyridoxamine as a cofactor. It seemed likely 
from the complementation data that EndQ formed the aminoimidazoline moiety and 
released enduracididine. 
  All  attempts  to  produce  an  EndQ  mutant that could  be  complemented  with 
enduracididine were unsuccessful. Further, some strains with endQ disruptions were 
found to produce  enduracidin. As such the  role  of EndQ  could not be  determined 
experimentally  using  a  complementation  assay.  Bioinformatic  analysis  of  endQ 
provided possible insight into these results. EndQ shows greater than 50% similarity 
to  several  proteins  belonging  to  the  GntR  family  of  transcriptional  regulators 
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Figure 3.15  Hypothetical biosynthesis  of  enduracididine based on complementation  assay 
results showing possible non-enzyme bound intermediates.suggesting EndQ may play a role in regulating enduracidin production in addition to 
acting as a cyclase. Disruption of the regulatory properties of EndQ could explain why 
the  disruptants  were  unable  to  be  complemented,  while  disruption  of  the 
aminotransferase activity could be overcome, though at significantly lower production 
levels, by EndP filling the role of EndQ.
  The bioinformatic analysis of endP, endQ and endR showed no known metal or 
cofactor  binding  sites besides  the  PLP binding  sites  in  endP  and  endQ.16,  18  The 
introduction  of  the  hydroxyl  group on  arginine  presented  a  difficult  biosynthetic 
question given the three enzymes possibly responsible. 
  Our collaborator, Dr. Silvaggi, sought an alternate route for the analysis of this 
biosynthetic pathway. As EndR and MppR are 73% identical, the results obtained from 
the  crystallography  on  MppR  should  translate  directly  to  EndR.  From  isolated 
recombinant MppR protein a  full  crystal  structure (2.2 Å resolution)  was obtained 
using the single-wavelength anomalous diffraction (SAD) method. MppR required an 
active site-bound ligand in order to crystallize. The active site of MppR with a HEPES 
molecule was shown to be  similar to the acetoacetate  family of enzymes. The key 
features  of  the  binding  site  are  Lys156,  Arg148  and  Glu283  surrounded  by  a 
hydrophobic  pocket  (Fig.  3.16).  Arg148  coordinates  the  carboxyl  group  of  the 
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Figure 3.16 A) The stereo view of the MppR binding pocket showing the electron density map 
of the bound HEPES molecule. B) illustration and distances  (Å) of hydrogen bonding and 
coordinating interactions between the binding pocket and the HEPES molecule.substrate or, in this case, the sulphonate of HEPES and assists in the alignment of the 
substrate  with Lys156 to form  a  Schiff  base  with  the  keto  group. The  negatively 
charged Glu283 hydrogen bonds with the piperazine ring of HEPES and is positioned 
to hydrogen bond with an arginic guanidine. The alignment suggests that MppR favors 
2-keto acids rather than the 3-keto acids of typical acetoacetate decarboxylases. These 
data  were  confirmed when  pyruvate, not acetoacetate,  was  observed  bound  in  the 
active site (Fig. 3.17). Interestingly, when MppR crystals were soaked in a solution of 
2-keto-4-OH arginate a 2-keto-enduracididine was observed bound to Lys156 in the 
active  site.  The  reaction  presumably  occurred  via  spontaneous  dehydration  and 
cyclization of 2-keto-4-OH arginate in solution since both enantiomers were observed 
LC-MS and NMR analysis of the supernatant. However, the crystal structure of 2-keto 
enduracididine  bound  to  MppR  showed that only the  correct 2-keto-4-R  End  was 
bound, suggesting that MppR is responsible for the cyclization reaction (Fig. 3.18). 
  The crystallographic data for MppR prompted a reassessment of the roles of the 
enzymes  in  enduracididine  biosynthesis  and  reevaluation  of  the  complementation 
assay results. For simplicity in discussion EndR/MppR will be referred to as EndR, 
EndP/MppP as EndP and  EndQ/MppQ as EndQ. The crystallographic  data  suggest 
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Figure 3.17 A) The stereo view of the MppR binding pocket showing the electron density map 
of the catalytic Lys  forming a Schiff base with pyruvate. B) Schematic of the binding pocket 
showing distances (Å) of possible coordinating interactions.EndQ  most  likely functions  as  a  transaminase  and  EndR  as  a  cyclase.  EndP  is 
proposed to function as a  transaminase affording  the  2-keto  species to be  used  by 
EndR, as evidenced by the complementation studies. Assuming no other enzymes are 
involved in enduracididine biosynthesis, if  EndP reacts with Arg  then it must also 
function as an oxidase given that EndR shows no signs of having oxidase functionality 
and appears to function as a cyclase. If the substrate of EndR is derived directly from 
arginine then an oxidation must occur. 
  The  possible  spontaneous  cyclization  of  2-keto-4-OH  arginate  decreases  the 
certainty of the previously hypothesized biosynthesis based on results from the feeding 
studies (Fig. 3.15). A conclusion that can be reached is that EndQ, assuming  it is the 
only transaminase functioning  in the pathway, can perform a transamination reaction 
with both 2-keto enduracididine and 4-OH Arg  based on the complementation of the 
endP  mutant  and  the  need  for  the  2-keto  group  to  facilitate  the  spontaneous 
elimination cyclization reaction.  Either EndP or  EndQ may be  responsible  for  the 
oxidation,  however  the  oxidative  agent  is  unknown  or  bound  to  the  protein  in  a 
manner not previously described in the bioinformatic databases. 
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Figure 3.18 A) The stereo view of the MppR binding pocket showing the electron density map 
of the catalytic Lys forming a Schiff base with 2-keto-4-R-enduracididine. B) Schematic of the 
binding pocket showing distances (Å) of possible coordinating interactions.  An alternate pathway for enduracididine formation was proposed by Dr. Silvaggi 
based on an observed reaction that occurred during experiments with pyruvate-bound 
MppR.  Soaking  MppR  in  a  solution  containing  pyruvate  and  4-formylimidazole 
produced a new chemical species bound to the active site identified as (3E)-4-(1H-
imidazol-5-yl)-2-oxobut-3-enoic  acid (Fig. 3.19). This product is proposed to result 
from  an  aldol  reaction  followed  by dehydration  (Fig.  3.19C).  From  this observed 
product it is proposed that pyruvate and 2-guanidinoethaldehyde, produced from Arg, 
could undergo an aldol reaction followed by a dehydration cyclization reaction while 
bound  to EndR/MppR. The  species was found  to be  bound  tightly to the enzyme 
preventing sufficient turnover to analyze the reaction kinetics. It is possible that EndP/
MppP or  EndQ/MppQ  could  act  as  a  transaminase  on  alanine  yielding  pyruvate 
specifically  for  this  reaction.  The  possible  source  of  2-guanidinoethaldehyde  is 
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Figure 3.19 The stereo view of the MppR binding pocket showing the electron density map of 
the catalytic Lys forming a Schiff base with (3E)-4-(1H-imidazol-5-yl)-2-oxobut-3-enoic acid. B) 
Schematic of the binding pocket showing distances (Å) of possible coordinating interactions. 
C) Proposed aldol reaction and dehydration reaction catalyzed by MppR.unknown, however, work done on the biosynthesis of nitroimidazole suggested that 4-
OH Arg serves as a precursor for the production of 2-guanidinoethaldehyde via retro-
aldol reaction. The aldehyde intermediate is then cyclized, possibly spontaneously, to 
form  the  aminoimidazole intermediate  which is  then  oxidized to  form the final  2-
nitroimidazole product (Fig. 3.20). The production of 4-OH Arg requires oxygen and 
suggests  that  a  flavin  or  transition  metal-based  oxygenase  is  responsible  for  the 
hydroxylation of Arg in Streptomyces eurocidicus.31 Additionally the possibility of a 
dehydrogenase forming the 2-keto-3-ene-arginate, a possible PLP-bound intermediate 
(Fig.  3.4),  from  2-keto  arginate  remains  plausible  biosynthetic  route  yet  to  be 
explored.
  As previously noted, the enduracidin biosynthetic gene cluster appears to contain 
only three genes for  the  production  of 4-OH Arg  and enduracididine.  The  further 
characterization of EndP and EndQ will determine whether 4-OH-2-ketoarginate  is 
produced by EndP and then cyclized on EndR or if EndR performs an aldol reaction 
followed  by  cyclization.  The  experimental  data  suggests  that  enduracididine 
biosynthesis goes through 4-OH Arg or a related intermediate (i.e. 3,4-didehydro Arg) 
and  that 4-OH Arg  can serve  as a  biosynthetic  intermediate  to rescue  enduracidin 
production in endP and endR  mutants. From the crystallization data, it appears the 
spontaneous  dehydration-cyclization  of  2-keto-4-OH  arginate,  to  form  2-keto 
enduracididine,  complements the  endR  mutant in  the  supplementation  studies. The 
complementation of the endP deletion mutant with 4-OH Arg indicates that EndQ can 
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Figure 3.20 Nitroimidazole biosynthesis as proposed by Nakane et al. requires the oxidation of 
Arg followed by the formation of the 2-keto group. A retro aldol reaction is  then catalyzed 
followed by cyclization and oxidation of the 2-amino group to form nitroimidazole. act as an aminotransferase for both 2-ketoenduracididine and 4-OH Arg. The lack of a 
monoxygenase in the end biosynthetic gene cluster suggests 4-OH Arg precursors may 
be  produced by gene products coded  for elsewhere  on the  chromosome. Complete 
analysis of the S. fungicidicus and Amycolatopsis hygroscopicus genomes may provide 
insight into the possible origin of these precursors. The final steps of cyclization and 
amine formation in enduracididine biosynthesis have been determined, however, the 
formation of 4-OH Arg and its possible precursors require further experimentation to 
determine.
73Experimental Procedures
Bacterial Strains, media and culture conditions
The wild type Streptomyces fungicidicus strain (ATCC21013)  and S. aureus (ATCC 
29213) were purchased from ATCC. EPI300TM-T1R (Epicentre) was used as host for 
fosmids and E. coli-Streptomyces shuttle vectors. The plasmid pIJ773 was provided by 
Professor  Keith  Chater  (JIC,  Norwich,  England).  ISP2  (Difco),  ISP4  (Difco)  and 
tryptic soy broth (Difco) and other media components were purchased from VWR. For 
initial  fluorine  incorporation  studies  DL-3-F-tyrosine  was  purchased  from  Sigma. 
Media and culture conditions for S. fungicidicus were as previously described.16
Disruption of endP, endQ and endR genes
Three  gene  disruption  plasmids  were  constructed  using  the  methods  previously 
described30:  pXY300∆endP  for  in-frame-deletion  of  endP  on  the  chromosome, 
pXY148-endQΩAmR  for  insertional  disruption  of  endQ  and  pXY17RΩAmR  for 
insertional disruption of endR. After completion of the gene disruption procedures in 
the enduracidin-producing wild-type strain of S. fungicidicus, we obtained the desired 
mutant strains Sf∆endP, SfendQΩAmR  and SfendRΩAmR. All  these  mutant strains 
were confirmed by Southern blot analysis. 
Southern blot analysis
Genomic  DNA from  wild  type  and  disruptant strains  was  prepared  as  described 
previously.30  Restricted  genomic  DNA was  separated  by  electrophoresis  in  0.8% 
agarose  gel  and transferred  onto positively charged nylon membrane (Roche). The 
DNA probe  was prepared  using  digoxigenin-labeled  dUTP  and  hybridization  was 
revealed using a digoxigenin-DNA detection kit (Roche).
Complementation studies
74Seed cultures for each strain (wild-type strain was used as a control) were innoculated 
and  grown  in  TSB  broth  (5 mL) in sterile  20 mL culture  tubes  for 24  hr. Sterile 
production  media  (25  mL  in  125  erlenmeyer  flasks  containing  a  spring)  was 
innoculated using 1 mL of seed culture and incubated at 29 °C and shaking at 200 
rpm. Solutions of enduracididine and hydroxyarginine (100 mg/mL in DI water) were 
sterilized by syringe filtration (0.2 µm). Cultures were supplemented with 30 mg  of 
compound on day 4, 20 mg on day 5, and 10 mg on day 6. After 11 days the culture 
mycelia were  pelleted  by centrifugation at 3000 rpm for  30  min. The  pellets were 
extracted using 70% aq. methanol overnight, concentrated in vacuo and analyzed via 
HPLC.
HPLC and mass spectroscopic analysis
HPLC analysis was performed using  a Shimadzu CBM-20 instrument equipped with 
an  SPD-20 diode  array detector monitoring  230, 254  and 270  nm wavelengths. A 
Phenomenex 4.6 x 100 mm Kinetex 2.6 µm XB-C18 column was used with a linear 
gradient from  10% MeCN in  water + 0.1% TFA to 100% MeCN over 13  min. to 
analyze  the  samples.  Mass spectrometric  analysis  was performed  using  a  Thermo 
Finnigan LCQ Advantage instrument in ESI+ mode. LCMS analysis was performed 
on  a  ABSciex  3200  Triple  Quadrupole  spectrometer  with  a  Shimadzu  CBM-20 
instrument using a gradient from 10% MeCN in 50 mM ammonium formate buffer to 
50% MeCN over 30 min with a flow rate of 0.5 mL/min using the Kinetex column. 
NMR analysis
NMR spectra were recorded using a Bruker DRX 300 MHz instrument (1H-300 MHz, 
13C-75 MHz). Data were processed and analyzed using Topspin ver 1.3 (Bruker) and 
MestReNova ver. 8.0.2-11021 (Mestrelab Research). 
Solvents and reagents
All reagents were purchased from Sigma Aldrich or Alpha Aesar. Allylglycine was 
75purchased as a racemic mixture of 95% purity and as L-allylglycine at greater than 
99%  purity.  Histidine  was purchased as  the  L form  as biological  grade. All  other 
reagents were  purchased  as ACS  reagent grade  products. Water was deionized  (18 
MΩ) using a Barnstead B-Pure filtration system. THF was distilled under Ar from a 
sodium-benzophenone  solvent  still  using  unstabilized  anhydrous  solvent. 
Triethylamine was purchased as ACS reagent grade and passed through a column of 
basic  alumina (50-200  µm)  prior  to  use.  Other  solvents  were  purchased  and  used 
without further purification. 
tert-Butyl 5-(iodomethyl)-2-oxo-tetrahydrofuran-3-ylcarbamate (2,3): A solution 
of iodine (26.45 g, 104 mmol) in THF (160 mL) was added dropwise at 0 °C to a 
solution of 1 (7.48 g, 34 mmol) in THF (120 mL) and 1M sodium bicarbonate (350 
mL). The reaction mixture was stirred in an ice bath for 5 hrs then quenched with 
saturated sodium sulfite (160 mL). The mixture was extracted with EtOAc and the 
combined organics were washed with water and brine, then dried over sodium sulfate. 
The solvent was removed under reduced pressure yielding an off-white solid. The cis 
isomers were separated by crystallization from EtOAc and hexanes precipitation of the 
mother liquor produced a mixture of the cis and trans isomers. Cis isomers 2 (9.81 g, 
28.7 mmol, 84%), 1H-NMR (300 MHz, CDCl3) δ (ppm): 1.46 (s, 9H), 1.87 (dd, J1 = 
12.3 Hz, J2 = 10.5 Hz, 1H), 3.02 (m, 1H), 3.32 (dd, J1 = 10.5 Hz, J2 = 7.2 Hz, 1H), 
3.45 (dd, J1 = 10.5 Hz, J2 = 4.8 Hz, 1H), 4.45 (m, 2H), 5.07 (bs, 1H).
Trans isomers 3 (0.98 g, 2.9 mmol, 9%) 1H-NMR (300 MHz, CDCl3) δ (ppm): 1.46 (s, 
9H), 2.41 (dd, J1 = 12.3 Hz, J2 = 10.5 Hz, 1H), 2.62 (m, 1H), 3.36 (m, 2H), 4.36 (m, 
1H), 4.75 (m, 1H), 5.06 (bs, 1H). LRMS, ESI (+) m/z = 342.0.
Cis  t-Butyl  5-(azidomethyl)-2-oxo-tetrahydrofuran-3-ylcarbamate  (4):  To  a 
solution of the iodides 2 and 3 (for 4-S-OH-L-Arg only 2 was used) (0.5 g, 1.47 mmol) 
in anhydrous N,N-dimethylforamide  (8 mL) sodium azide (0.476 g, 7.3 mmol) was 
76added  and  the  mixture  was  stirred  at  40  oC  for  17  hrs.  After  cooling  to  room 
temperature, the reaction mixture was poured into ice and extracted with ethyl acetate. 
The combined organic extracts were washed with water as well as brine, dried and 
evaporated in vacuo to give an oil that was purified by flash chromatography (ethyl 
acetate: hexane = 3:7) to afford 4 (368 mg, 1.43 mmol, 98%) as a clear solid. 1H-NMR 
(300 MHz, CDCl3) δ (ppm): 1.46 (s, 9H), 1.87 (q, J = 11.4 Hz, 1H), 2.77 (m, 1H), 3.50 
(dd, J1 = 13.5 Hz, J2 = 5.4 Hz, 1H), 3.64 (dd, J1 = 13.5 Hz, J2 = 3.6 Hz, 1H), 4.48 (m, 
1H), 4.57 (m, 1H), 5.09 (bs, 1H); 13C-NMR (75 MHz, CDCl3) δ (ppm): 28.63, 33.04, 
50.98, 53.29, 75.65, 80.80, 155.31, 173.83. LRMS, ESI (+) m/z = 257.1.
4–Hydroxylarginine HCl salt (7): To a solution of 6 (0.60 g, 1.26 mmol) in dioxane 
(11  mL)  was  added  1N-NaOH  (15  mL)  and  the  mixture  was  stirred  at  room 
temperature for 18 hrs. After being cooled to 0 oC, 4N-HCl (15 mL) was added slowly 
and the mixture was stirred at room temperature for 4 hrs. Then the solvents were 
evaporated to give a white solid. The product was chromatographed on a Dowex 50W 
X 8 (hydrogen form, 200 mesh) column and eluted using a gradient, with water and 
4N-HCl yielding  7 (250 mg, 95 mmol, 75% yield) as a foamy solid. 1H-NMR (300 
MHz, D2O) δ (ppm): 2.09 (q, J = 12 Hz, 1H), 2.81 (m, 1H), 3.43 (dt, J1 = 15.3 Hz, J2 = 
5.4 Hz, 1H), 3.66 (d, J1 = 15.3 Hz, 1H), 4.50 (dd, J1 = 12 Hz, J2 = 9 Hz, 1H), 4.78 (m, 
1H); 13C-NMR (75 MHz, D2O) δ (ppm): 172.85, 157.26, 77.60, 49.24, 43.35, 29.23; 
LRMS ESI (+) m/z = 190.1.
N’,N”-Di-Boc-guanidine (10): To a solution of 9 (2.4 g, 25 mmol) in H2O (25 mL) 
was added NaOH (4.1 g, 100 mmol) and dioxane (50 mL). The solution was cooled in 
an ice bath and Boc2O (12.26 g, 55 mmol) was added and allowed to come to ambient 
temperature over 20 hrs. The  reaction was concentrated to one  third volume under 
reduced  pressure,  diluted  with  water  and  extracted  with  EtOAc.  The  combined 
organics were washed with 10% citric acid, water and brine then dried over Na2SO4 
77and  the  solvent  removed  in  vacuo.  The  crude  product  was  purified  via  flash 
chromatography (silica gel, 1:4 EtOAc:Hexanes) yielding 10 (3.6 g, 13.9 mmol, 55% 
yield) as a white amorphous solid. 1H-NMR (300 MHz, CDCl3) δ (ppm): 10.42 (br s, 
1 H), 8.44 (br s, 2H), 1.38 (s, 18H) 13C NMR (75 MHz, CDCl3) δ 158.43, 152.41, 
80.99, 27.88. LRMS, ESI (+) m/z = 260.2.
N-Tf,  N’,N”-di-Boc-guanidine  (11):  To  a  solution  of  8  (2.5  g,  9.6  mmol)  and 
triethylamine  (1.4  mL,  9.6  mmol)  in  distilled  DCM  (50  mL)  at  -78  ºC 
trifluoromethanesulfonic  anhydride  (1.7  mL,  9.6  mmol)  was  added  dropwise 
maintaining  temperature below -65 ºC. The reaction was allowed to warm to 10 ºC 
over 5 hrs. The reaction was quenched with 1M potassium bisulfate and then washed 
with water. The organics were dried over Na2SO4 and the solvent removed in vacuo. 
The crude product was purified via flash chromatography (silica gel, DCM) yielding 
11 (2.4 g, 6.13 mmol, 64% yield) as a white  crystaline solid.  1H-NMR (300 MHz, 
CDCl3) δ (ppm): 10.04 (br s, 2 H), 1.5 (s, 18H). 13C NMR (75 MHz, CDCl3) δ 151.44, 
148.89, 119.26 (q, J=320.1 Hz), 85.90, 27.70. LRMS, ESI (+) m/z = 391.1.
L-Histidine methyl ester (12): To a stirred mixture of L-His (3 g, 19.34 mmol) and 
MeOH (180 mL) in an ice bath was added thionylchloride (2.81 mL, 38.67 mmol) 
over 1 hr. The insoluble His dissolved after half of the thionyl chloride was added. The 
flask  was  removed  from  the  ice  bath  and  equipped  with  a  reflux  condenser  and 
refluxed 18 hrs. The reaction was then cooled and the solvent was removed under 
reduced pressure. The product was crystallized from MeOH–ether yielding 12 (4.28 g, 
17.7 mmol, 91% yield) as white crystals. 1H NMR (300 MHz, methanol-d4) δ 8.67 (d, 
J = 1.4 Hz, 1H), 7.41 (d, J = 1.1 Hz, 1H), 4.47 (t, J = 6.8 Hz, 1H), 3.81 (s, 3H), 3.53 – 
3.29 (m, 2H);  13C NMR  (75 MHz, methanol-d4) δ 167.94, 134.57, 126.92, 118.49, 
52.88, 51.66, 25.09; LRMS ESI (+) m/z = 170.1.
78(S,Z) 2,4,5-tris(benzamido)pent-4-enoate methyl ester (13): To a stirred solution of 
12  (500  mg,  2.07 mmol)  in water  (17  mL) in  an  icebath  was added concurrently 
benzoyl chloride (1.44 mL, 12.4 mmol) in benzene (10 mL) with Na2CO3 (2.85 g, 26.9 
mmol)  over 1  hr. The  reaction  was the  stirred  at ambient temperature  for  24  hrs. 
EtOAc (40 mL) was then added and the organic layer was isolated and the solvent 
removed under reduced pressure. The product was dissolved in 3:2 THF:1M NaHCO3 
(30  mL) and  stirred  for  24  hours.  The  precipitate  was  removed  by filtration  and 
washed with water. The solid was dissolved in MeOH and precipitated affording  13 
(871 mg, 1.84 mmol, 89% yield) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 
9.80 (d, J = 9.3 Hz, 1H), 9.54 (s, 1H), 8.75 (d, J = 7.9 Hz, 1H), 7.98 – 7.72 (m, 6H), 
7.65 – 7.36 (m, 9H), 6.84 – 6.57 (m, 1H), 4.70 (bs, 1H), 3.62 (s, 3H), 3.20 (td, J = 
12.6, 11.0, 5.1 Hz, 1H), 2.81 (dd, J = 14.3, 10.2 Hz, 1H); 13C NMR (75 MHz, DMSO-
d6) δ 172.28, 166.63, 166.00, 163.38, 134.46, 133.96, 133.46, 131.92, 131.66, 131.50, 
128.62, 128.32, 128.00, 127.47, 127.32, 117.28, 115.32, 52.05, 51.12, 33.89. LRMS, 
ESI (+) m/z = 472.2.
(S,Z) 2,4,5-tris(benzamido)pentanoate methyl ester (14):  To a solution of 13 (400 
mg, 0.85 mmol) dissolved in EtOH (60 mL) and 2:1 AcOH:H2O (10 mL) was added 
Pd/C (542 mg, 0.25 mmol). The reaction was purged with H2 gas 4 times and then 
heated to 60ºC. After stirring for 18 hrs the reaction was cooled and filtered through a 
pad of celite. The solvent was then removed under reduced pressure. The product was 
dissolved  in EtOH with heating, allowed to cool  to  ambient temperature and then 
precipitated with the addition of Et2O affording 14 (359 mg, 0.77 mmol, 90% yield). 
1H NMR (300 MHz, DMSO-d6) δ 8.80 (dd, J = 10.0, 7.7 Hz, 1H), 8.61 (t, J = 5.9 Hz, 
0.5H), 8.52 (t, J = 6.2 Hz, 0.5H), 8.39 (dd, J = 11.4, 8.6 Hz, 1H), 7.94 – 7.73 (m, 6H), 
7.63 – 7.36 (m, 9H), 4.68 (q, J = 7.1 Hz, 0.5H), 4.59 – 4.47 (m, 0.5H), 4.44 – 4.26 (m, 
1H), 3.63 (s, 1.5H), 3.56 (s, 1.5H), 3.63 – 3.40 (m, 2H), 2.33 – 1.99 (m, 2H);  13C 
79NMR (75 MHz, DMSO-d6) δ 173.07, 172.40, 166.96, 166.75, 166.74, 166.69, 166.63, 
166.20,  134.97,  134.78,  134.64,  134.58,  134.11,  133.65,  131.56,  131.36,  131.17, 
131.08,  131.00,  128.34,  128.26,  128.20,  128.17,  128.10,  127.57,  127.44,  127.41, 
127.38, 127.36, 127.29, 52.01, 51.96, 50.31, 50.08, 47.47, 46.61, 43.37, 42.67, 32.92, 
32.17. LRMS, ESI (+) m/z = 474.2.
(2-S, 4-RS) 2,4,5-Triaminopentanoate (15): A solution of 14 (300 mg, 0.64 mmol) in 
6 N HCl (30 mL) was refluxed under Ar for 18 hrs. The reaction was then cooled to 4 
ºC and washed with Et2O three times. The aqueous layer was separated and the solvent 
removed under reduced pressure. The product was not purified further and taken on to 
the next reaction.
Enduracididine (16): Method A: The solid was dissolved in 100 mM Na3PO4 buffer 
pH 11 (16 mL) was added BrCN (360 mg, 3.4 mmol) dissolved in water (8 mL) in 
portions over 2.5 hr. The solvent was removed under reduced pressure. The solid was 
dissolved in 6 N HCl (40 mL) and refluxed for 2 hr. The reaction was allowed to cool 
to ambient temperature and the solvent removed under reduced pressure. The product 
was dissolved in minimal water, adjusted to pH 7 and chromatographed on Dowex 
50X2 cation exchange resin (H+ form) Eluting with water 1 N HCl, 2 N HCl and 4 N 
HCl affording the product 16 (2 HCl salt form) in the 4 N HCl fractions (47 mg, 0.19 
mmol, 30% yield) as a brown solid. 1H NMR (300 MHz, D2O) δ 4.39 – 4.27 (m, 1H), 
4.26 – 4.09 (m, 1H), 3.82 (td, J = 9.7, 5.6 Hz, 1H), 3.40 (dd, J = 9.9, 6.5 Hz, 1H), 2.26 
– 1.95 (m, 2H); 13C NMR (75 MHz, D2O) δ 177.97, 177.70, 159.28, 159.15, 55.96, 
55.71, 52.11, 51.92, 48.19, 48.07, 35.45, 35.29; LRMS ESI (+) m/z = 173.1. 
  Method B: The solid (from 12.2 mmol) was dissolved in water (240 mL) and 
adjusted to pH 11 with 1 N NaOH. BrCN (5.8 g, 55 mmol) in water (210 mL) was 
added dropwise over 2.5 hr. The pH was carefully monitored and maintained above 
pH 10 with 1 N NaOH over the duration of the reaction. After an additional 30 min of 
80stirring the solvent was removed under reduced pressure. The solid was dissolved in 6 
N HCl (600 mL) and refluxed for 2 hr. The reaction was allowed to cool to ambient 
temperature  and  the  solvent  removed  under  reduced  pressure.  The  product  was 
dissolved  in  minimal  water,  adjusted  to  pH 7  and  purified  using  cation exchange 
chromatography Dowex 50X2 resin (H+ form) Eluting with water, 1 N HCl, 2 N HCl 
and 4 N HCl affording the product 16 (2 HCl salt form) in the 4 N HCl fractions (2.16 
g, 8.79 mmol, 72% yield) as a grey solid. 1H NMR (300 MHz, D2O) δ 4.39 – 4.27 (m, 
1H), 4.26 – 4.09 (m, 1H), 3.82 (td, J = 9.7, 5.6 Hz, 1H), 3.40 (dd, J = 9.9, 6.5 Hz, 1H), 
2.26 – 1.95 (m, 2H);  13C NMR (75 MHz, D2O) δ 177.97, 177.70, 159.28, 159.15, 
55.96, 55.71, 52.11, 51.92, 48.19, 48.07, 35.45, 35.29; LRMS ESI (+) m/z = 173.1.
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86CHAPTER FOUR
SEMISYNTHETIC MODIFICATION OF ENDURACIDIN
Neal GoebelIntroduction
  The bioactivity of enduracidin relies on binding as a dimer to the proximal end 
of Lipid II. The depsipeptide  portion of enduracidin forms a binding  pocket which 
coordinates with the sugar diphosphate linkage of Lipid II.1 The role of the lipid tail of 
the  peptide,  however,  is  less  defined.  Crystal  structures  of  the  related  antibiotic 
ramoplanin suggest the lipid tail associates with the lipid membrane, possibly being 
responsible for bringing  enduracidin in proximity to Lipid II (Fig. 4.1A).2 The lipid 
tail  of  enduracidin  also  decreases  the  solubility  of  the  compound  and  may  be 
associated  with  the  observed  accumulation  phenomenon  of  enduracidin  in 
intramuscular and intravenous injections.3 Our investigations have proceeded in the 
interest of understanding the biosynthesis of the lipid tail and altering it to improve the 
physical properties of enduracidin.
  The  lipid tail  is produced through primary metabolic pathways using  a  valine 
(for End A) or isoleucine (for End B) derived starter unit followed by the addition, 
reduction and dehydrogenation of four acetate units forming  a saturated lipid chain 
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Figure 4.1 A)  Crystal structure of a ramoplanin dimer  (yellow  and purple)  interfacing with 
detergent  molecules  (green), chloride  ions  (magenta)  and  ordered water  molecules  (red). 
Figure  is  from  Hamburger  et  al.2  B)  The  lipid  tail  structures  of  enduracidin  (blue)  and 
ramoplanin (cyan).branched  at the  10  carbon  (Fig.  4.1B).4  Four  gene  products  are  predicted  to  be 
involved in the activation and tailoring  of the 2-Z, 4-E configured unsaturated lipid 
tail:  Orf35, Orf39, Orf44 and Orf45. Orf35, from bioinformatic analysis, correlates 
well with the ACP/PCP family proteins and is likely responsible for correlating with 
the  NRPS  unit EndA to  produce  the  acyl-Asp starter  unit.  Bioinformatic  analysis 
predicts that Orf39 and Orf44 are Acyl-CoA dehydrogenases while Orf45 is an Acyl-
CoA  lygase/hydrogenase  fusion  protein.  Based  on  the  data  from  friulimicin 
biosynthesis,  it is hypothesized  that Orf45  is responsible  for the  activation of  the 
carboxylic acid as the CoA-thioester and introduction of a double bond.5 Orf39 and 
Orf44 are then predicted to be responsible for the introduction of the second double 
bond and isomerization of the first to the Z configuration (Fig. 4.2). These genes all 
have  homologs in the  ramoplanin biosynthetic gene  cluster. Ramoplanin contains a 
shorter lipid tail which shares its double bond pattern with enduracidin (Fig. 4.1B).6 
For the  study of  the  biosynthetic  enzymes,  the  production  of  enduracidin  analogs 
having partially reduced and isomerized lipid tails was undertaken.
  The planned modification of the enduracidin lipid tail raised further interest in 
replacing  the  tail completely. The  lipid tail, bound  as an amide  to the  enduracidin 
depsipeptide  ring,  has  limited  synthetic  accessibility  while  incorporated  into 
enduracidin.    Hydrolysis  via  mild  acid  or  base  is  likely to  have  no  selectivity. 
Enzymatic deacylation is a known method of deactivating  lipopeptide antibiotics in 
bacteria.7  Enzymatic  deacylation  activity  has  been  found  to  be  linked  with  ring 
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Figure  4.2  Possible  routes  for  the  introduction  of  the  C2  and  C4  double  bonds  and   
isomerization of the C2 alkene.cleavage  reactions  particularly  at  the  lactone  ester  linkage.8  The  potentially  low 
production yield of deacylated peptide and the time required to isolate the hydrolytic 
proteins lead to the exploration of an alternative method. After concluding our studies 
on the deacylation of enduracidin, an enzymatic deacylation method was successfully 
adapted  for  ramoplanin.9 Unfortunately,  there  was  insufficient time  to  pursue  this 
method for use with enduracidin.
  The  presence  of  the  two  double  bonds  in  the  lipid  tail  provides  a  potential 
chemical  handle  for  the  production  of  altered  enduracidins. The  semisynthesis  of 
ramoplanin lipid tail analogs by Ciabatti et al. demonstrated the use of an ozonolysis 
reaction to cleave the  lipid tail, affording  an aldehyde as a synthetic handle on the 
peptide. The aldehyde was then converted to the benzylamine via reductive amination 
90
O
HN
NH2
NH2
O
HN
NH
NH
Fmoc
Fmoc
O
O
HN
NH
NH
Fmoc
Fmoc
NH
O
HN
NH
NH
Fmoc
Fmoc
NH2
NH
NH
Fmoc
Fmoc
i ii iii iv
O
H
N O
N
H
N
O
Alkyl
O
N
H
NH
Alkyl
N
H
O
H
N
HO
HO
OH
HO
R
O
HN
R
O HN
R
O
NH
R
O
NH
O
NH
R
OR
A
B
C
Figure 4.3 A) Removal of the lipid tail of ramoplanin as described by Ciabatti et al. starting with 
i)  protection  using  Fmoc-OSu,  ii)  Ozonolysis  with  PPh3  reductive  work  up,  iii)  reductive 
amination using NaBH3CN and iv) Edman degradation. B) Proposed lipid tail replacements for 
enduracidin and tetrahydroxylation of the alkenes. C) Potential Diels-Alder reactions with the 
lipid tail alkenes.and  the  asparagine-1  α-amine  freed  via  Edman  degradation  (Fig.  4.3A).10  In  an 
attempt  to  improve  enduracidin  solubility,  our  investigation  focused  on  the 
introduction of  polar/charged groups  into  the  lipid  tail  to  improve  solubility (Fig. 
4.3B). As an  alternative modification the  use  of Diels-Alder  type reactions for the 
introduction of new function groups was also explored (Fig. 4.3C). The final lipid tail 
modification planned was the hydroxylation of the double bonds. 
  The introduction of nitro groups on the Hpg residues of enduracidin failed during 
incorporation experiments with 3-nitro-Hpg  as described in chapter 2. Therefore, a 
semisynthetic  approach  to  nitro  enduracidin  (NO2-End)  was  investigated.  Several 
examples  in  the  literature  demonstrate  the  nitration  of  tyrosine  in  proteins  with 
peroxynitrite11 and tetranitromethane (TNM)12 and the neutrally buffered conditions 
are amenable to enduracidin. Nitration reactions on tyrosine using nitrite and nitrate 
salts under acidic conditions have also been demonstrated on natural products.13 The 
nitration of the β-OH enduracididine-containing antibiotic mannopeptimycin suggests 
that  the  enduracididine  residues  of  enduracidin  will  not  be  altered  under  these 
conditions.14 Furthermore, the antifungal lipodepsipeptide FR901469 was successfully 
nitrated,  also  suggesting  that  enduracidin  would  tolerate  the  reaction  conditions. 
FR901469 required protection of the Orn δ-amine with Boc.15 As the lipid tail work 
also  required  the  preparation  of  protected  enduracidin,  the  production  of  starting 
material was simplified. Additionally, personal experience isolating enduracidin by a 
1:1:1 MeOH:Acetone:HCl (1 N) extraction indicates the that acidic conditions should 
not interfere in the development of a viable approach to NO2-End.
91Results and Discussion
Biosynthesis of the lipid tail
  The disruption of the genes orf39, orf44 and orf45 had the potential of producing 
several  forms of  the  lipid  tail  (Fig. 4.4A). To aid  in  the  identification of  analogs 
produced  in  low  yield,  a  series  of  reduced  lipid  tail  enduracidin  analogs  were 
produced. Tetrahydro-enduracidin A (H4-End A) was the initial target for preparation. 
While enduracidin has poor solubility in ethanol, it has excellent solubility in DMF. 
Enduracidin A,  dissolved  in  DMF,  subjected  to  hydrogenation  with  palladium  on 
carbon under a  H2  atmosphere  for  30  min,  successfully formed three  enduracidin 
compounds (Fig 4.4B). Isolation of the peaks 1-3 and MS analysis revealed that peaks 
1 and 3 were both forms of dihydro-enduracidin A (H2-End A) and peak 2 was H4-End 
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Figure 4.4 A) Possible lipid tail configurations resulting from the disruption of orf39, orf44 and 
orf45. i) enduracidin A, ii) 2-trans enduracidin A, iii) 2-cis-4,5-H2-enduracidin A, iv) 2-trans-4,5-
H2-enduracidin A and v)  H4-enduracidin A. B)  HPLC UV chromatogram (216 nm–blue, 254 
nm–black) of the hydrogenation reaction, ambient temperature for 30 min. 93
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Figure 4.5 A) ESI (+) MS spectra showing the [M+2H]2+ ions  of 1) Enduracidin A, 2) 2-cis-H2-
End A,  3)  2-trans-H2-End A and  4)  H4-End A. B)  1H NMR  spectra for  the corresponding 
compounds. The lipid tail olefin protons are labelled indicating the carbon to which it is bound.A (Fig  4.5A). The different retention times suggested that the  two  dihydro species 
have different configurations of a single double bond. NMR analysis of peak 2, H4-
End A, confirmed the reduction of the two olefins (Fig. 4.5B-4). The spectra of peak 1 
showed  proton  shifts  consistent  with  2-cis-H2  End  A (Fig.  4.5B-2).  Peak  3  was 
determined to be 2-trans-H2 End A as the H2 signal had a coupling constant to H3 of 
15.7  Hz  (Fig.  4.5B-3).  Upon  further  experimentation  with  reaction  time  and 
temperature it was discovered that 2-cis-H2-End A was the favored product when the 
reaction temperature was lowered to 0 ºC. Increased yield of H4-End A was achieved 
by  extending  the  reaction  time  to  3  hrs.  The  production  of  the  trans  isomer  is 
postulated  to result from  dihydro-palladium  acting  as a Lewis acid, catalyzing  the 
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Figure 4.6 Mechanism for the palladium-mediated  isomerization of the cis olefin to the trans. 
A hydride addition forms the palladium enolate intermediate allowing for rotation around the 
C2-C3 bond.
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Figure 4.7 Disk  diffusion assay of enduracidin lipid tail reduction products  against S. aureus 
using 1 mg of A) Enduracidin A, B) H4-Enduracidin A, C) 2-trans-H2-End A and D) 2-cis-H2-End 
A.isomerization  of  the  double  bond  (Fig  4.6).16  The  three  purified compounds were 
subjected to a disk-diffusion antibacterial assay. No significant change in bioactivity 
was observed compared to End A (Fig. 4.7). 
  With the End A lipid tail analog standards in hand, the analysis of mutants was 
undertaken. The Acyl-CoA dehydrogenase portion of orf45 was disrupted by insertion 
of  the  apramycin  resistance-conferring  transposon  cassette  Tn5AT,  producing  the 
mutant Sf45dh::Tn5AT.  HPLC  analysis of methanolic  culture  extracts  showed  two 
new  compounds  at 12  and  22 min  (Fig. 4.8A).  MALDI-TOF MS  analysis of  the 
isolated products indicated that the compounds were H4-End A and B (Fig. 4.8B). The 
production of H4-End by Sf45dh::Tn5AT suggests that the hydrogenase  of Orf45 is 
responsible  for the  introduction  of first double bond, because  the formation of the 
second olefin by Orf39/Orf44 would not be possible without the C2-C3 double bond 
providing conjugation to the carbonyl.
  To further study the biosynthetic pathway, the strain Sf44::Tn5AT was produced 
having  an  insertional  disruption of  the  putative  acyl-CoA dehydrogenase  encoding 
orf44. With the aid of the semisynthetic standards it was determined by HPLC and MS 
that Sf44::Tn5AT also produced H4-End A (Fig. 4.9). The production of H4-End by the 
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Figure 4.8 A) HPLC  chromatogram of extracts  from wild-type S. fungicidicus (bottom)  and 
orf45 disruptant Sf45dh::Tn5AT (top). Enduracidin A and B are labelled with asterisks. New 
enduracidin compounds produced by the mutant strain are labelled with ‘#’. MALDI-TOF MS 
analysis of the 12 min peak, H4-End A (top) and 22 min peak, H4-End B (Bottom) showing the 
[M+H]+ ion.orf44  mutant  suggests  that  the  dehydrogenase  function  of  Orf45  may  rely  on 
interacting with Orf44. 
  To fully explore this method of examining the lipid tail biosynthetic pathway, the 
deletion of orf39 was undertaken. The newly formed deletion mutant SfΔ39 was found 
to have greatly reduced enduracidin production and a product with the same mass as 
enduracidin that was hypothesized to be 2-trans-4-trans enduracidin. Since a standard 
for this isomer had not been produced, the compound was isolated and characterized 
via  NMR to determine  the  configuration  of the  C2-C3 olefin.  Comparison of  the 
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Figure 4.9 A) HPLC chromatogram of the Sf44::Tn5AT culture extract. The new compound is 
indicated with an asterisk. B) ESI (+) MS spectrum of the 9.6 min. peak showing the [M+3H]3+ 
ion. The neutral mass of 2356.8 Da corresponds with H4-End A.
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Figure 4.10 Double quantum filtered COSY NMR spectra for A) Enduracidin A and B)  the 
peptide  isolated  from  SfΔ39AmR.  The  olefinic  lipid  tail  correlations  are  labeled  in  each 
spectrum. double  quantum  filtered  COSY  spectra  of  enduracidin A  and  the  SfΔ39  product 
showed  them  to  be  identical  (Fig.  4.10).  For  further  confirmation,  the  coupling 
constant for the H2/H3 signals, JH2/H3, was measured at 11.3 Hz, consistent with the 2-
cis-4-trans  configuration  of  enduracidin.  The  reduction  of  enduracidin  production 
suggests that orf39 is involved in the formation of the lipid tail diene although the role 
as an isomerase or dehydrogenase is uncertain with the current evidence. 
  Because H4-End can be produced in fair quantity by Sf45dh::Tn5AT it may be 
possible  that Orf39,  Orf44 and Orf45 do not prevent some altered lipid tails from 
being incorporated into enduracidin. Based on this assumption, the loading onto Orf35 
or the condensation reaction with Asp1 on the NRPS, EndA, are two possible points of 
inhibition. If Orf39 were responsible for the introduction of the C4-C5 double bond 
the  observed  results  would  indicate  that  another  dehydrogenase  was  capable  of 
complementing  the  deficiency.  Additionally,  it  would  suggest  that  Orf44,  having 
isomerase functionality, could not function as the production of 2-cis-H2-End was not 
observed in the orf39 mutant. The 2-cis lipid should be incorporated as readily as the 
saturated lipid tail as both can take on a similar conformation to the natural 2-cis-4-
trans lipid tail. If Orf39 is responsible for the isomerization of the C2-C3 olefin then 
Orf44, as a dehydrogenase, may have a side reaction isomerizing  the C2-C3 olefin. 
The  uncatalyzed  isomerization of the first double  bond or complementation  of the 
mutant by another dehydrogenase/isomerase may explain the lowered production of 
enduracidin. The  production  of H4-End by both orf44 and orf45  mutants seems to 
suggest the two may interact to form a complex, although there is no direct evidence. 
Disabling  Orf44  using  point mutations and an  in-frame  deletion  could give further 
evidence  of  such  an  interaction.  Ultimately,  these  hypotheses  require  significant 
investigation, likely requiring  purified  proteins and  an NMR or crystal structure to 
demonstrate the complexing of the two proteins. 
  From the observed results and the bioinformatic analysis it appears that Orf45 is 
responsible  for the formation  of the CoA thioester and the introduction of the first 
97double bond. The second double bond is then introduced and isomerized by Orf44 and 
Orf39.
Lipid tail removal with ozone 
  The semisynthetic approach to modifying enduracidin was predicated heavily on 
the  work  done  by Ciabatti  et  al.  on  the  antibiotic  ramoplanin.10  Enduracidin  and 
ramoplanin are similar in their structure and even share the same biological target. As 
semisynthetic  work  began,  however  several  differences  became  apparent.  The 
preliminary step in modifying  the enduracidin lipid tail was the protection of the δ-
amine of Orn4. The protection of ramoplanin’s Orn4 and Orn10 was achieved using 
Fmoc-OSu and TEA in DMF at ambient temperatures. When these conditions were 
used  with  enduracidin  no  reaction  was  observed.  Varying  the  reaction  conditions 
revealed that the presence of DMF prevented the reaction from occurring. Running the 
reaction in 50% aq. THF with bicarbonate or TEA at ambient temperature produced 
Fmoc-protected  enduracidin  (Fmoc-End).  However,  Boc  protection  using  Boc-
anhydride with bicarbonate in 70% MeOH gave excellent yields. Therefore, the higher 
yield and easy purification of Boc-End led to it being used for most of the reactions.
  For the  semisynthetic experiments enduracidin extracted from  Enradin™ was 
utilized.  It  was  found  that  enduracidin  from  a  1:1:1  MeOH:acetone:HCl  (1  N) 
Enradin™ extract could be bound to activated charcoal. The charcoal was then washed 
with water, and an aqueous methanol gradient followed by the elution of enduracidin 
with 70% isopropanol. The dried material was readily prepared at ~70% purity and 
used  as  a  starting  material  for  the  Boc  reactions on  a  gram  scale  with  excellent 
conversion. The Boc-protected enduracidin was used in the subsequent semisynthetic 
experiments. 
  Ozonolysis  reactions  have  been  used  successfully  on  peptides  previously, 
including  ramoplanin.10, 13a, 17 However, the ozonolytic  cleavage of the  enduracidin 
lipid  tail  diene  was  unsuccessful  under  numerous  conditions.  MS  analysis  of  the 
products of Boc-End using  the reaction conditions described by Ciabatti et al. with 
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Figure 4.11 Mass  spectra of Boc-End ozonolysis  products  under various  conditions. A)  3:1 
MeOH:DMF, DMS, 5 min., -78 ºC; B) 3 Å MeOH, DMS, 5 min., -78 ºC; C) 1:2 DCM:MeOH, 
DMS, 4 min., -78 ºC; D) Close-up of the singly charged degradation products  between 1150 
and 1400 Da; E) 1:2 DCM:MeOH, DMS, 2 min., -78 ºC; F) 1:2 DCM:MeOH, DMS, 1 min., -78 
ºC; G) 1:2 DCM:MeOH, TPP, 2 min., -78 ºC; H) 1:2 DCM:MeOH, Pyr, 2 min., -78 ºC; I) 1:2 
DCM:MeOH, Zn-AcOH, 2 min., -78 ºC; J) Pooled HPLC fractions of reaction I.dimethylsulfide  (DMS)  was  unsuccessful  (Fig.  4.11A).  Degradation  products  are 
observed as a broad peak in the spectrum. The reaction was run in anhydrous MeOH 
with DMS as the reducing  agent, similar to the conditions used by Black et  al.13a, 
except for maintaining  the  reaction  at -78 ºC and limiting  ozone  exposure to five 
minutes. The result, as observed by ESI MS, was degradation products present in the 
mass range of double and triple charged enduracidin, however, the major peaks were 
at m/z 1116.5, 1127.5, 1132.5 and 1144.5 Da, not the expected value of 1159.5 (Fig. 
4.11 B). Furthermore, degradation products at m/z 803 and 402 Da were observed. In 
an attempt to reduce degradation, the solvent was changed to 1:2 DCM:MeOH. When 
ozone was blown over the reaction until it turned blue (~ 4 min) the MS spectrum still 
showed a significant amount of degradation (Fig. 4.11C and D). The observed peaks 
had a charge of +1 indicating that the peptide had been cleaved, but the products could 
not be readily identified. Reducing the exposure time to ozone reduced the degradation 
of the compound, however oxidative side reactions were still proceeding (Fig. 4.11E 
and F). Changing the reducing  agent was postulated to improve the reaction. Use of 
triphenylphosphine and Zn-AcOH were both unsuccessful (Fig. 4.11G and I). The use 
of  pyridine  as an additive  for  ozonolysis reactions has been reported  previously.18 
Pyridine  is oxidized  to  its  N-oxide  form  which reacts with  the  carbonyl  peroxide 
during the rearrangement of the primary ozonide (Figure 4.12). Hence, potential side 
reactions of the ozonide should be negated and immediate formation of the aldehyde 
should occur. When run in the presence of pyridine, ozonolysis caused degradation of 
enduracidin  similar  to  what was  observed  previously (Fig  4.11H). The  Zn-AcOH 
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Figure 4.12 Proposed mechanism for the reduction of carbonyl peroxides by pyridine N-oxide 
after the fragmentation of the primary ozonide.reactions were observed to produce strange clusters during MS analysis. The product, 
a five  minute  wide, polar   peak on HPLC, was isolated and analyzed by MS  (Fig. 
4.11J).  Unfortunately the  spectrum provided no insight into the  structure since  the 
product appears to have further decomposed. 
  The  required  isolation  of  enduracidin  from  aqueous  solvent systems  prior  to 
ozonolysis was identified early in the process as a possible source of side reactions 
forming peroxides and other reactive oxygen species. To reduce water bound to the 
peptide, the compound was repeatedly dissolved in anhydrous DMF/MeOH and then 
dried under high  vacuum. Further investigation  of the  degradation  focused  on  the 
functional group differences between ramoplanin and enduracidin. The presence of the 
carboxylate of Asp1, dichlorophenol of Dpg-13 and the two guanidines of End-16 and 
End-11 are the main differences.  Dichlorophenol is readily oxidized by ozone under 
aqueous conditions.19 Additionally, given the possibility that all water associated with 
enduracidin may not be eliminated, reactive peroxide species may be contributing to 
the degradation of enduracidin. Concluding that ozonolysis was not a viable method of 
removing the lipid tail, alternate approaches to modifying enduracidin’s lipid tail were 
undertaken. 
Diels-Alder reaction: maleimides
  Diels-Alder type  reactions  provide  a  method of  selectively reacting  with  the 
alkenes of enduracidin. The maleimide and nitroso dienophiles were chosen as they 
have both been shown to be highly reactive, introduce new functional groups and may 
be used to form a library of related compounds for analysis. A series of maleimide 
compounds can be readily produced synthetically from commercially available amines 
and maleic anhydride. Maleimides have been used as highly reactive dienophiles for 
the  ligation  of  compounds  to  DNA.20  The  commercially  available  N-methyl-
maleimide  was examined first. Reactions were  performed  in  a variety of  different 
solvents as observed in the literature (DMF, DMF-water, DMF-NaOAc buffer, MeCN-
water, MeOH, MeOH-water and MeOH-NaOAc buffer).21 Maleimide reactions have 
101been used  in  aqueous,  ambient temperature  reactions, and thus the  reactions with 
enduracidin were run for 24 hrs at ambient temperature. Only the DMF reaction was 
heated because the presence of water and protic solvents would potentially hydrolyze 
enduracidin in the time required for the ambient temperature reaction. HPLC and MS 
analysis of the products revealed that no reaction took place (Fig. 4.13). The likely 
limitation for the reaction is the energy required to rotate the diene around the C3-C4 
bond  achieving  the  proper  configuration  for  a  Diels-Alder  reaction.  No  further 
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Figure 4.13 A)  HPLC chromatograms  showing the analysis  of the maleimide reaction with 
Boc-End under various conditions. Boc-End, a set of three peaks, is indicated with an asterisk. 
Enduracidins A and B are indicated with a ‘#’. B) ESI (+) MS analysis of representative of the 
whole reaction series
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Amaleimide reactions were pursued.
Diels-Alder reaction: nitrosotoluene
  Nitroso compounds have been shown to  react with dienes in various systems 
with a  variety of substrates.22 Particularly, the reaction of nitroso-benzene  with the 
rapamycin triene suggested that a selective reaction with the enduracidin diene may be 
possible.23 For the introduction of polar/charged groups, the oxazine ring  formed in 
the  reaction  carries  a  charge  under  neutral  conditions,  potentially  improving 
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Figure 4.14 A) ESI (+) MS analysis  of the NO-Toluene MeOH, CuI reaction representative of 
the  catalyzed reactions.  B)  HPLC  chromatograms  showing the analysis  of  the maleimide 
reaction with Boc-End under various  conditions. Boc-End, a set of three peaks, is  indicated 
with an asterisk. Enduracidins A and B are indicated with a ‘#’.
A
Benduracidin’s  solubility.  For  the  construction  of  semisynthetic  libraries,  nitroso 
compounds can be prepared from numerous precursors or purchased. Nitroso Diels-
Alder  reactions  require  heat for  the  reaction  to  proceed. The  Lewis  acid  catalyst 
copper iodide has previously been used to facilitate Diels-Alder reactions.22c, 24 For a 
dienophile  the  commercially available  2-nitroso-toluene  (NO-toluene)  was selected 
because it is similar to the nitroso-benzene  used by Graziani et al. on rapamycin.23 
Catalytic reactions were run for 24 hrs at ambient temperature while the uncatalyzed 
reactions were run at 70 ºC. The catalyzed reactions were checked by MS, with the 
lack of a peak at 1288 Da indicating that no reaction had occurred (Fig. 4.14A). As no 
product was  observed,  the  reactions  were  run an additional  18  hrs at 70  ºC. The 
reactions were cooled, dried and redissolved in 70% MeOH. HPLC analysis indicated 
that all of the conditions failed to produce a new compound (Fig. 4.14B).  
  The cis configuration of the first double bond in the enduracidin diene may be a 
factor in  the dienophile reactions. The cis configuration  of  the C2  olefin  sterically 
restricts rotation to the required planar double bond orientation due to the proximity of 
H5 and the carbonyl oxygen. As such, the diene likely cannot enter a configuration 
capable of a Diels-Alder reaction without more energy or the isomerization of the C2 
alkene. The failure of the reactions lead to further experimentation using  a diene to 
react with one of the lipid tail double bonds. 
Diels-Alder reaction: Danishefsky’s diene
  To  study  the  Diels-Alder  reactions  with  an  olefin  from  the  lipid  tail, 
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Figure 4.15 ESI (+) MS spectra showing the crude products from the A) first reaction of Boc-
End and Danishefsky’s Diene. B) A higher resolution spectra of the 1311.5 Da compound from 
the second reaction with Danishefsky’s diene.Danishefsky’s  diene  (trans-1-methoxy-3-trimethylsilyloxy-1,3-butadiene)  was 
selected as it is readily available, is highly reactive and produces a ketone which can 
serve  as a  synthetic handle. Using  a  similar  set of  reaction  conditions to the NO-
toluene  reactions,  Danishefsky’s  diene  was  found  to  react  reproducibly  with 
enduracidin in a heated DMSO-toluene solvent system, as observed by MS (Fig. 4.15), 
however,  the  observed  ion  (m/z=1311.5  [M+2H]2+)  does not  correspond  with  the 
addition  of  Danishefsky’s  diene  to  enduracidin  (expected  m/z=1313.5  [M+2H]2+). 
HPLC analysis provided little evidence as to the identity of the new compounds (Fig. 
4.16). The reaction was repeated on a larger scale and the product isolated by HPLC. 
The isolation of the new compound proved to be challenging. HPLC fractionation of 
the crude product resulted only in the isolation of enduracidin (Fig. 4.17). If a [4+2] 
cycloaddition occurred it is possible that the product is sufficiently unstable under the 
acidic  conditions  required  for  purification  that  a  retro  Diels-Alder  reaction  is 
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Figure  4.16  HPLC  chromatograms  showing  the  Boc-End/Danishefsky’s  diene  reaction 
products  from various  conditions. Enduracidin is  labelled with an ‘#’ and Boc-End with  an 
asterisk. occurring.  Further  research  into  this modification  should  involve  the  oxidation  or 
hydrogenation of the alkene formed by the Diels-Alder reaction, potentially trapping 
the product.
Lipid tail modification: alkene dihydroxylation
  To further explore the potential for modifying the lipid tail, hydroxylation of the 
alkenes with osmium tetroxide was examined. Dihydroxylation reactions have proven 
to be robust reactions tolerated by various functional groups. Notably, OsO4 catalyzed 
reactions have been performed on rapamycin and gluconucleosides,25 and the reaction 
can be run in the presence of water and various protic solvents.26 The dihydroxylation 
of alkenes conjugated to a carbonyl has been demonstrated previously.27 Interestingly, 
the  selective  dihydroxylation  of  a  C4-C5  olefin  in  a  carbonyl  conjugated  diene 
suggested  that  4,5-dihydroxyenduracidin  (4,5-(OH)2-End) may  be  produced.28  The 
reaction proceeded smoothly on unprotected enduracidin using  three equivalents of 
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Figure 4.18 ESI (+) MS spectrum of the dihydroxylation reaction of enduracidin. The labeled 
signals  are the +2 ions: A) m/z=1194.5, (OH)2-End A; B)  m/z=1201.5, (OH)2-End B; C)  m/
z=1205.5, (OH)2-End A Na+ adduct; D) m/z=1211.5, (OH)4-End A; E) m/z=1212.5, (OH)2-End 
B Na+ adduct; and F) m/z=1222.5, (OH)4-End A Na+ adduct.
                                                      
        
Figure 4.17 ESI (+) MS spectrum of the pooled HPLC fractions from four min. to 8 min. of the 
spectrum. Enduracidin A and B are present in the [M+2H]2+ form at m/z =1177.5 and 1185.5 
respectively.  The  additional peaks  are the sodium (+11)  and  potassium (+18)  adducts  of 
enduracidin A and B.NMO and catalytic  OsO4. MS  analysis of  the  reaction mixture  indicated that both 
dihydroxy  and  tetrahydroxy  species  were  produced  (Fig.  4.18).  HPLC  and  MS 
analysis  indicated  that  a  total  of  six  products  were  produced;  three  hydroxylated 
species for each form of enduracidin (Fig 4.19). Peaks A, B and F were isolated by 
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Figure 4.20 Proton NMR spectra comparing the hydroxylated enduracidins  with End A. The 
lipid tail olefinic protons are indicated on each spectra with an asterisk. A) End A; B) Peak A, 
(OH)4-End B; C) Peak B, (OH)2-End A; and D) Peak F, (OH)2-End A.
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Figure  4.19  HPLC  chromatogram  showing  the  separation  of  hydroxyenduracidin  species 
which were identified by ESI MS as A)  (OH)4-End A, B) (OH)2-End A, C) (OH)4-End B, D) 
(OH)2-End  B  E)  (OH)2-End A and  F)  (OH)2-End B.  Unreacted  enduracidin A  and  B  are 
indicated with asterisks.HPLC. Analysis by 1H NMR indicated that the reactions had occurred on the lipid tail 
alkenes and confirmed that peak A was (OH)4-End A (Fig 4.20). Further analysis using 
2D COSY NMR experiments indicated that peak B was 2,3-(OH)2-End A and peak F 
was  4,5-(OH)2-End  B  (Fig.  4.21).  As  the  compounds  represented  each  of  the 
hydroxylation  patterns,  they  were  analyzed  in  a  bioassay  against  S.  aureus  to 
investigate the effects of hydroxylation on bioactivity. End A and ampicillin were used 
as references in the assay (Fig. 4.22). Compared to End A, 2,3-(OH)2-End B was four-
fold less active, 4,5-(OH)2 End A was 16-fold less active and (OH)4-End A was over 
16-fold less active, showing no bioactivity at 25.6 µg/mL. Ampicillin was found to be 
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Figure 4.21 A) COSY spectrum of peak B showing the labelled correlations: a) H2-H3; and b) 
H3-H4. B) COSY spectrum of peak F showing the labelled correlations: a) H3-H4; b) H4-H5; 
and  c)  H5-H6.  Lipid  tail  structures  of  each  compound  are  shown  to  the  right  of  their 
corresponding spectra.
O
NH HO
HO8  times  less  active  than  End  A with  a  MIC  of  12.8  µg/mL  in  this  assay.  The 
enduracidin lipid tail is responsible for coordinating  an enduracidin dimer with the 
lipid  membrane,  bringing  it in  proximity to  Lipid  II. These  data  suggest that the 
introduction of polar/hydrogen bond-forming groups on the proximal end of the lipid 
tail may significantly decrease membrane affinity and coordination, thereby reducing 
potency. Optimal ramoplanin bioactivity against S. aureus is achieved with a C7 to C8 
lipid tail (the natural product being 7-Me-octa-2,4-dienoic acid). A decrease to C6 was 
observed  to result in  a  four-fold loss of activity, consistent with  the hydroxylation 
results.10 The combined results suggest that further attempts to introduce polar groups 
onto the lipid tail of enduracidin would not be productive, even if increased solubility 
was achieved.
Nitration of enduracidin
  The  synthetic  potential  for  introducing  a  nitro  group  into  enduracidin  holds 
interest  for  our  semi-synthetic  work.  As  incorporation  of  NO2-Hpg  directly  into 
enduracidin  was  unsuccessful,  chemical  nitration  of  the  natural  product  was 
undertaken. Previous work on other lipopeptides suggested several  methods for the 
nitration  of  enduracidin.  Mannopeptimycin,  FR901469  and  pneumocandin  have 
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Figure  4.22  Chart  showing  the  percent  growth  inhibition  of  S.  aureus  by  the  various 
hydroxylated  enduracidins  compared  with  End A and ampicillin.  Standard  of  deviation is 
shown.successfully undergone  aromatic nitration with the use of nitrate/nitrite salts and an 
organic acid (Fig 4.23).13a, 14-15 The literature indicated that neat TFA or AcOH were 
needed for the reaction. Previous work producing NO2-Hpg  showed that the AcOH-
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Figure 4.24 HPLC chromatograms showing the A) TFA-KNO3 and B) AcOH-NaNO2 reactions.
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Figure 4.23 Structures  of FR901469 (left), mannopeptimycin (center) and Pneumocandin B0 
(right).NaNO2 was an effective reagent for the nitration of Hpg. Unfortunately, the nitration 
of  enduracidin  with  NaNO2  under  various  conditions  proved  to  be  unsuccessful 
(Figure  4.24B).  The  use  of  KNO3  with  both  acetic  acid  and  TFA proved  to  be 
unsuccessful. No nitrated forms of enduracidin were observed via HPLC (Fig. 4.24A). 
MS analysis of the isolated peaks indicated that the KNO3 reaction failed to produce a 
new compound while the nitrite reaction degraded the enduracidin (Fig. 4.25). As such 
a new method of nitration was investigated.
  The  nitration  of tyrosine  on  proteins has been accomplished  through  several 
methods. Studies of the cellular response to oxidative stress have focused heavily on 
peroxynitrite which can be easily produced from nitrite and  azide.11a, 12e, 29 For the 
nitration  of  enduracidin,  however,  the  degradation  of  unsaturated  lipids  by 
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Figure 4.26 HPLC chromatogram showing the product of the TNM-10 mM NH4OAc buffer 
reaction. The peaks were identified as starting material.
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Figure 4.25 ESI (+)  MS spectra of pooled HPLC  fractions  from the A) TFA-KNO3  and B) 
AcOH-NaNO2 reactions.peroxynitrite negates its use in this synthesis.30 Tetranitromethane (TNM) has been 
used  for  the  nitration of  proteins and  peptides,  having  been used  under numerous 
buffer  conditions  and  in  the  presence  of  alcohols.  This  nitration  reaction  was 
performed on enduracidin under numerous conditions using  literature  methods, but 
proved to be unsuccessful, as evidenced by the acetate buffer reaction (Fig. 4.26).12a, 
12d,  31  The  overall  strategy  of  introducing  nitro  groups  on  the  Hpg  residues  of 
enduracidin both chemically and through mutasynthesis proved unsuccessful and was 
abandoned.   
112Experimental Procedures
Bacterial strains, plasmids, fosmids, media and culture conditions
  S. fungicidicus (ATCC21013) and Escherichia  coli  S17-1  (ATCC47055) were 
purchased from ATCC. E. coli DH5α (Life Technologies, Inc.) and EPI300TM-T1R 
(Epicentre) were routinely used as hosts for E.  coli plasmids, fosmids and E. coli-
Streptomyces shuttle  vectors. The pGEM-T easy cloning  vector was obtained from 
Promega. Plasmids pSET152 and pIJ773 were  provided by Professor Keith  Chater 
(JIC, Norwich, England). ISP2 (DifcoTM ISP Medium 2), ISP4 and TSB (BactoTM 
Tryptic Soy Broth) were purchased from VWR. Media and culture conditions for S. 
fungicidicus were previously described.32 
DNA isolation and manipulations. Isolation of chromosomal
  DNA from  S. fungicidicus wild-type  and the  mutant strains, and  agarose  gel 
electrophoresis were performed according  to Kieser et al.33 QIAprep Spin Miniprep 
kits  (Qiagen)  were  used  to  prepare  plasmids  and  fosmids  from  E.  coli  strains. 
Restriction  endonucleases,  DNA  ligase,  DNA  polymerase,  Klenow  enzyme  and 
alkaline phosphatase were purchased from Roche and Invitrogen and used according 
to the manufacturers’ recommendations. Primers used for PCR and DNA sequencing 
were synthesized by Fisher. PCR products and restriction fragments from agarose gels 
were purified using QIAquick Gel Extraction kits from Qiagen. 
Construction of the Tn5AT cassette for in vitro transposon mutation
  The  Tn5AT  cassette  was  designed  to  combine  three  genetic  elements:  the 
transposon Tn5,  oriT and aaC3(IV). Tn5 is specifically and uniquely recognized by 
Tn5 transposase (Epicentre) and readily inserts into high G + C Streptomyces DNA 
cloned into E. coli plasmids and fosmids.34 The gene oriT is required for the conjugal 
transfer of the DNA from E. coli S17-1 to Streptomyces and  aaC(3)IV is an E. coli-
113Streptomyces bifunctional selective  marker conferring  apramycin  resistance.35 Both 
oriT and aaC3(IV) were excised from plasmid pIJ773 as a XbaI fragment and then 
cloned into the transposon donor plasmid pMODTM-2(MCS) (Epicentre), previously 
linearized  with  XbaI.  The  resulting  plasmids  pXYTn5ATa  and  pXYTn5ATb  only 
differ  by  the  orientation  of  XbaI  fragment  and  were  used  to  prepare  the  Tn5AT 
cassette by digestion with PvuII according to the manufacturer’s specification. 
In vitro transposon mutation and selection of targeted fosmids
  To  generate  a  library of  random  mutagenized  fosmids  for  gene  replacement 
experiments,  we  conducted  in  vitro  transposon  insertional  mutation  of  fosmids 
pXYF305 and pXYF607, carrying  segments of the end gene cluster.34 The reaction 
was performed at 37 °C for 2 h after mixing 10 µL (0.5 µg) fosmid template DNA, 2 
µL (20 ng) Tn5AT cassette DNA, 2 µL 10 x reaction buffer, 1 µL Tn5 transposase and 
5  µL  sterile  water.  Transformation  of  E.  coli  competent  cells  EPI300TM-T1R 
(Epicentre) with the  transposon reaction mixture was performed by electroporation. 
Mutagenized fosmids were selected on LB agar plates supplemented with 100 µg/ml 
apramycin. Plates were  incubated overnight at 37 °C and surviving  colonies were 
randomly  picked  and  grown  in  LB  liquid  culture  with  addition  of  100  µg/ml 
apramycin. The  mutagenized fosmid DNA from these  colonies and control fosmid 
pXYF305 were digested with HindIII and analyzed by electrophoresis on 1% agarose 
gels. The Tn5AT cassette contains a single HindIII site which is useful when screening 
for single versus multiple disruption events over the fosmid insert. No HindIII sites are 
present in the  fosmids pXYF305 and pXYF607 inserts and only one HindIII site is 
present in the fosmid vector. Hence, digestion with HindIII readily identifies fosmids 
with a single insertion of Tn5AT by the presence of two bands in the gel. Colonies 
carrying  mutagenized  fosmids  with  a  single  transposon  insertion  were  randomly 
selected and grown in liquid culture to permit fosmid isolation and identification of the 
disrupted gene. Screening was conducted by sequence analysis using  the primer 5′- 
114AAGGAGAAGAGCCTTCAGAAGGAA-3′,  which  corresponds  to  a  region  of  the 
apramycin resistance  gene. In this manner, fosmid pXYF305D6 was found to have 
Tn5AT inserted into orf45 at nucleotide position 111335 and pXYF607D21 had the 
cassette inserted into orf44 at nucleotide position 109247 (GenBank Accession No. 
DQ403252).
Disruption of orf44 and the dehydrogenase domain of orf45
 T h e   g e n e   r e p l a c e m e n t   f o s m i d s   p X Y F 3 0 5 D 6   a n d   p X Y F 6 0 7 D 2 1   w e r e  
individually transformed into E. coli S17-1 by electroporation and then introduced into 
S. fungicidicus by intergeneric conjugation. Exconjugant colonies surviving apramycin 
selection were passed through two rounds of sporulation without antibiotic selection to 
create the stable mutant strain via double crossover homologous recombination. The 
resulting  spores were pooled, diluted and  plated on ISP2 agar plates supplemented 
with 50 µg/ml apramycin. The apramycin-resistant colonies were randomly picked and 
used to inoculate TSB liquid culture for preparation of the genomic DNA for Southern 
analysis. The confirmed mutant strains were designated as Sf44::Tn5AT for the orf44 
disruptant and Sf45dh::Tn5AT for the orf45 disruptant.
Insertional inactivation and in-frame deletion of orf39
Two recombinant plasmids, pXY301∆39 and pXY301∆39AmR, were constructed for 
in-frame  deletion  and  insertional  disruption  of  orf39,  respectively.  To  construct 
pXY301∆39, two PCR fragments 39∆1 and 39∆2, each containing a portion of the in-
frame deleted gene and its up or downstream contiguous sequence, were  amplified 
from fosmid pXYF305. HindIII and BamHI restriction sites were designed into PCR 
primers 39∆1pf (5′-TATAAAGCTTACGACGGAGGACGGGCCGCT-3′, HindIII site 
is  in  bold)  and  39∆1pr  (5′-TAAAGGATCCGGCCCCGGTGACGATCGCGGT-3′, 
BamHI site is in bold) used to amplify fragment 39∆1. BamHI and EcoRI restriction 
sites   were   introduced   into   PCR   primers   39∆ 2pf   (5′ -
AATTGGATCCCGGCAGGTCACGGGGTCGGTCATC-3′, BamHI site  is in bold) 
115and  39∆2pr  (5′-CGTTGAATTCCCGCCGGGTCGAGGATGC-3′,  EcoRI  site  is  in 
bold) used to amplify fragment 39∆2. PCR was conducted in a final volume of 100 
µL  containing  100  ng  of  pXYF305  DNA,  150  pmol  of  each  primer,  20  µL  5  x 
AccuPrimeTM GC-Rich  buffer A (Invitrogen) and 1  µL polymix  (added at 80 °C) 
from Expand Long Template PCR System (Roche). PCR was performed as follows: 1 
cycle at 95 °C for 3 min and at 80 °C for 1 min, 30 cycles at 95 °C for 1 min, at 55 °C 
for 1 min and at 72 °C for 2 min. The reaction was terminated with one extension 
cycle at 72 °C for 10 min. PCR products were gel-purified and cloned into the pGEM-
T easy vector to afford the plasmids pGEMTE-39∆1 and pGEMTE-39∆2. Error-free 
inserts  of  pGEM-T  easy  derivatives  were  then  confirmed  by  sequencing.  The 
appropriately restricted and gel-purified fragments 39∆1(949 bp) and 39∆2 (858 bp) 
were  simultaneously  ligated  with  the  HindIII-  and  EcoRI-linearized  E.  coli-
Streptomyces temperature-sensitive  conjugal  vector  pXY301 to yield  pXY301∆39. 
pXY301 was derived from pXY300 where the BamHI site was eliminated by treating 
the  BamHI  digested vector with  Klenow enzyme  followed  by self-ligation.36 After 
confirming  the  in-frame  deletion  assembly by restriction analysis  and  sequencing, 
pXY301∆39 was linearized with BamHI  and ligated with the  apramycin resistance 
gene-containing  fragment  (AmR).  The  resulting  plasmid  was  designated 
pXY301∆39AmR. The 0.9 kb AmR fragment was amplified from plasmid pSET152 
using  the  primers (AmRpf: 5′-CACGGATCCGGTTCATGTGCA-3′ and AmRpr: 5′-
ATCGGATCCCACGTGTTGC-3′.  pXY301∆39AmR  was  introduced  into  S. 
fungicidicus  by conjugation  and  the  rest  of  the  gene  disruption  procedures  were 
performed as described previously. The orf39 disruptant was confirmed by Southern 
analysis and designated as Sf∆39AmR. To generate an orf39 in-frame deletion mutant 
strain, pXY301∆39 was introduced into the mutant strain Sf∆39AmR by conjugation. 
Replacement of the apramycin resistance marker with the in-frame deletion copy of 
the  orf39  gene  in  mutant  Sf∆39AmR  was  confirmed  by  apramycin-sensitive 
116phenotype and Southern analysis.   The corresponding  mutant strain was designated 
Sf∆39.
DNA sequencing and analysis
  DNA sequencing was performed at the OSU Center for Genome Research and 
Biocomputing using  the Amplitaq dye-terminator sequencing  system (Perkin Elmer) 
and  Applied  Biosystems  automated  DNA  sequencers  (models  373  and  377). 
Nucleotide sequences were determined for both strands. Sequence analysis was carried 
out using the VectorNTI (Invitrogen) software. Nucleotide and amino acid sequence 
similarity  comparisons  were  carried  out  in  public  databases  using  the  BLAST 
program.37 
Sf∆39 metabolite analysis and purification 
  Fermentation conditions for the production of enduracidins from S. fungicidicus 
strains, and the processing of the mycelia to yield an extract containing the peptides, 
have been previously described.38 The extracts were passed through Varian HF Mega 
Bond  Elut-C18  columns  and  sequentially  eluted  with  H2O,  25%,  50%,  100% 
acetonitrile and 50% acetonitrile in 50 mM phosphate buffer, pH 4.3. Fractions were 
concentrated  and  analyzed  by  HPLC  and  bioassay.  Those  containing  the  desired 
compounds were  combined and further purified by semi-preparative  reversed-phase 
HPLC with a C18 column (Gemini 10 µM, 250 x 10 mm) from Phenomenex. Solvent 
A was water with 0.1% TFA, and solvent B was acetonitrile with 0.1% TFA. The flow 
rate was 5 ml/min starting  with 25% B, increasing to 65% B over 30 min, and then 
held for a further 10 min. Separate 1 min fractions were collected over the entire run. 
Those  containing  the  pure  compounds  were  pooled  for  further  MS  analysis  and 
bioassay. 
Southern blot analysis
117Genomic  DNA from  wild  type  and  disruptant strains  was  prepared  as  described 
previously.38  Restricted  genomic  DNA was  separated  by  electrophoresis  in  0.8% 
agarose  gel  and transferred  onto positively charged nylon membrane (Roche). The 
DNA probe  was prepared  using  digoxigenin-labeled  dUTP  and  hybridization  was 
revealed using a digoxigenin-DNA detection kit (Roche).
Disk diffusion antibacterial assay
A solution of each antibiotic to be test was prepared in 75% aq. methanol (50 mg/mL). 
Each sterile disk was treated with 20 µL antibiotic solution and allowed to air dry. The 
disks were then placed on a TSB agar plate inoculated with S. aureus ATCC 29213. 
The  plate  was  incubated  at 37  ºC  for 16  hr.  Diameter of  zone  of  inhibition;  The 
resulting  zones  of  inhibition  were  measured:  Enduracidin A:  14  mm,  2-trans-H2 
enduracidin A: 17 mm, 2-cis-H2 enduracidin A:  15 mm, and H4-enduracidin A:  14 
mm.
Microdilution antibacterial assay
A culture of S. aureus was grown over night at 37 °C on tryptic soy agar. A single pure 
colony was used to inoculate a 5 mL TSB culture which was shaken at 150 rpm for 4 
hrs at 37 °C. Antibiotic samples were prepared in 50% aq. MeOH and 20 µL of each 
dilution was loaded into wells on a 96-well Microtest plate (Falcon). To each test well 
was added 80 µL of sterile TSB followed by 100 µL of ~5 × 105 cells per mL of S. 
aureus  in  TSB.  Each  antibiotic  was  tested  concurrently  three  times  at  each 
concentration.  Initial  absorbance  readings at 600 nm  were  recorded and  the  plates 
were then sealed with parafilm and incubated at 37 °C for 16 hrs. Final absorbance 
readings were taken and percent growth calculated using the untreated well values as 
the reference. The percent inhibition was then calculated (100% – percent growth), the 
average was taken and standard deviations were calculated. MICs were determined as 
the lowest antibiotic concentration that exhibited >95% growth inhibition.
118Sf∆39 isolate HPLC and mass spectroscopic analysis
HPLC analysis was performed using  a Shimadzu CBM-20 instrument equipped with 
an SPD-20 diode array detector monitoring  230, 254 and 270 nm wavelengths. For 
general enduracidin analysis a Phenomenex  4.6 x 100 mm Kinetex 2.6 µm XB-C18 
column was used with a linear gradient from  10% MeCN in water + 0.1% TFA to 
100% MeCN over 13 min. For the analysis of ozonolysis reactions the method was 
modified to a gradient from 5% MeCN in water + 0.1% TFA to 50% MeCN over 20 
minutes and a five minute  gradient to  100% MeCN at 1.5 mL/min.  Semisynthetic 
compounds were purified using a Phenomenex Synergi Polar column (10 x 250 mm, 5 
µm)  using  a  20  gradient from  15%  MeCN  in  water  + 0.1%  TFA to 50%  MeCN 
followed by a 10 minute gradient to 100% MeCN at 3 mL/min. Mass spectroscopic 
analysis was performed using  a Thermo-Finnigan LCQ Advantage instrument in ESI 
(+) mode.
NMR analysis
NMR  spectra  were  recorded  using  a  Bruker  300  MHz  instrument  for  synthetic 
compounds (1H-300 MHz,  13C-75 MHz). Proton NMR experiments on enduracidin 
were  performed  using  a  Bruker  Avance  III  700  MHz  instrument  (1H-700  MHz, 
13C-175 MHz). NMR experiments on H2 and H4-End samples were performed on a 
Bruker 600 MHz instrument (1H-600 MHz,  13C-150 MHz) in d6-DMSO-D2O (1:4). 
Enduracidin  and  fluorinated  samples  were  dissolved  in  a  mixture  of  2:5  D2O: 
methanol-d4. The  proton shifts are  referenced  to methanol-d4 (3.31 ppm). Fluorine 
NMR spectra were recorded using  a Bruker DPX-400 instrument (376 MHz) and a 
Bruker AvanceIII 500 instrument (471 MHz). Analysis of spectra was performed using 
Topspin  ver  1.3  and  3.1  (Bruker)  and  MestReNova  ver  8.0.2-11021  (Mestrelab 
Research).
Solvents and reagents
119All solvents and reagents were  purchased from  Sigma Aldrich or Alpha Aesar and 
used as received unless stated. All  reagents were  purchased as ACS  reagent grade 
products. Water was deionized (18 MΩ) using a Barnstead B-Pure filtration system. 
THF  was distilled  under Ar  from  a  sodium-benzophenone  still  using  unstabilized 
anhydrous solvent. Triethylamine was purchased as ACS  reagent grade and  passed 
through  a  column  of  basic  alumina  (50-200  µm)  prior to use.  DMSO,  DMF and 
MeOH were  purchased  as  anhydrous  solvents.  MeOH was  further  dried  over  3Å 
molecular sieves. Other solvents were purchased and used without further purification. 
Lipid tail reduction methods and Sf∆39 isolate NMR analysis
Enduracidin A: 1H NMR (700 MHz, 1:4 d6-DMSO: D2O, 25 ºC) Alkyl tail shifts: δ 
2.23 (m, 2H, H-6), 5.71 (d, J=11.3, 1H, H-2), 6.27 (dt, J = 14.7, 7.2 Hz, 1H, H-5),   
6.63 (m, 1H, H-3), 7.24 (m, 1H, H-4); LRMS ESI (+) m/z 1177.4 [M+2H]2+.
2-cis-H2 enduracidin A: A mixture of enduracidin A (4 mg, 1.7 µmol) and 5% Pd/C 
(0.36 mg, 0.17 µmol) in DMF (3 mL) was stirred under hydrogen atmosphere (1 atm) 
at 0 ºC for 30 min. The reaction was filtered through a plug of celite and a syringe 
filter  (0.2µm). The  filtrate solvent was evaporated under  reduced pressure and the 
residue purified by HPLC, retention time 10 min. 1H NMR (600 MHz, 1:4 d6-DMSO: 
D2O, 35 ºC) Alkyl tail shifts: δ 2.61 (m, 2H, H-4), 5.91 (d, J=11.5 Hz, 1H, H-2), 6.22 
(dt J=11.5, 7.5 Hz, 1H, H-3); LRMS ESI (+) m/z 1178.5 [M+2H]2+.  
2-trans-H2 enduracidin A: A mixture of enduracidin A (4 mg, 1.7 µmol) and 5% Pd/
C (0.36 mg, 0.17 µmol) in DMF (3 mL) was stirred under hydrogen atmosphere (1 
atm) at ambient temperature for 60 min. The reaction was filtered through a plug  of 
celite and a syringe filter (0.2µm). The filtrate solvent was evaporated under reduced 
pressure and the residue purified by RP-HPLC, retention time 15.1 min. 1H NMR (600 
MHz, 1:4 d6-DMSO: D2O, 35 ºC) Alkyl tail shifts: δ 2.25 (m 2H, H-4), 6.03 (d, J=15.5 
Hz, 1H, H-2), 6.89 (m, 1H, H-3); LRMS ESI (+) m/z 1178.4 [M+2H]2+.
120H4 enduracidin A: A mixture of enduracidin A (4 mg, 1.7 µmol) and 5% Pd/C (0.36 
mg, 0.17 µmol) in DMF (3 mL) was stirred under hydrogen atmosphere (1 atm) at 
ambient temperature for 3 hrs. The reaction was filtered through a plug of celite and a 
syringe filter (0.2µm). The filtrate solvent was evaporated under reduced pressure and 
the residue purified by RP-HPLC, retention time 14.2 min. 1H NMR (600 MHz, 1:4 
d6-DMSO: D2O, 35 ºC) Alkyl tail shifts were not determined; LRMS ESI (+) m/z 
1179.5 [M+2H]2+.
Sf∆39 enduracidin A isolate: 1H NMR (700 MHz, 1:4 d6-DMSO: D2O, 25 ºC) Alkyl 
tail shifts: δ 2.23 (m, 2H, H-6), 5.71 (d, J=11.3, 1H, H-2), 6.27 (dt, J = 14.7, 7.2 Hz, 
1H, H-5),   6.63 (m, 1H, H-3), 7.24 (m, 1H, H-4);  LRMS  ESI (+)  m/z 1177.4 [M
+2H]2+.
Lipid tail ozonolysis methods
Orn4-N-Boc-enduracidin: To a solution of enduracidin (3.0 g, 1.3 mmol) in 70% 
aqueous MeOH (100 mL) was added NaHCO3 (2.2 g, 25.5 mmol) followed by Boc2O 
(2.84 g, 12.7 mmol) at ambient temperature. The reaction was stirred for 24 hrs. under 
Ar and monitored by HPLC (Kinetex column method). After conversion of the starting 
material (rt = 4.7 and 4.9 min) to product (rt = 5.7 and 5.9 min) was observed the 
reaction was cooled in an ice bath and acidified with AcOH (15 mL). After the solvent 
was removed under reduced pressure the crude  product was dissolved in DMF and 
precipitated with EtOAc. The solid is collected by filtration and washed with ether 
then water. The product is then dissolved in 2:2:1 anhydrous methanol:EtOAc:toluene 
and  the  solvent  removed  yielding  Boc-End  (2.3  g,  0.94  mmol,  74%)  as  a  white 
powder.  LRMS  ESI (+)  m/z =  1227.5  (Boc-End  A)  and  1234.5  (Boc-End  B)  [M
+2H]2+.
Orn4-N-Fmoc-enduracidin To a  solution of enduracidin (200 mg, 0.085 mmol) in 
50% aqueous THF (10 mL) was added NaHCO3 (440 mg, 5.1 mmol) followed by 
Fmoc-ONSu (440 mg, 1.3 mmol) at ambient temperature. The reaction was stirred for 
12118 hrs. under Ar and monitored by HPLC (Kinetex column method). After conversion 
of the starting  material (rt = 4.7 and 4.9 min) to product (rt = 5.8 and 6.0 min) was 
observed the reaction was acidified with AcOH (3 mL). After the solvent was removed 
under reduced pressure the crude product was dissolved in DMF and precipitated with 
EtOAc. The solid is collected by filtration and washed with EtOAc and water. The 
product is then dissolved in 2:2:1 anhydrous methanol:EtOAc:toluene and the solvent 
removed yielding Fmoc-End (100 mg, 0.039 mmol, 46%) as a white powder. LRMS 
ESI (+) m/z = 1288.5 (Boc-End A) and 1295.5 (Boc-End B) [M+2H]2+.
Ozonolysis  general  method  Ozone  was  bubbled  into  a  solution  of  protected 
enduracidin (10 mg, 4 µmol) in solvent (5 mL) with stirring  in a flame dried flask 
under Ar  at -78 ºC. After the specified time, Ar was bubbled through the solvent for 
10 min, and then  the reducing  agent was added. The  reaction was then allowed to 
warm  to ambient temperature  over 5 hrs. The  solvent was removed  and the  crude 
product dissolved in 70% aqueous MeOH for analysis. Only degraded product was 
observed  in  the  reaction  mixtures.  Starting  material:  Boc-End  was  used  for  the 
examination  of  reaction  conditions.  Solvents:  MeOH,  2:1  MeOH:DCM,  1:1 
MeOH:DCM,  2:1  MeOH:DMF,  2:1  DCM:DMF,  and  4:1  DCM:DMF.  Reducing 
reagent: DMS, TPP and Zn-AcOH were used in each of the solvent systems while Pyr 
was only used in MeOH-DCM solvents as prescribed in literature.18a  
Lipid tail Diels-Alder reactions
N-Me-Maleimide/Enduracidin reaction A solution of Boc-End (10 mg, 4 µmol) in 
solvent (300 µL) with N-methylmaleimide (1 mg, 8 µmol) in a 4 mL vial was stirred 
under Ar for 48 hrs. The reaction was monitored by MS. The solvent was removed 
under reduced pressure. The crude product was dissolved in 70% aqueous MeOH and 
filtered, yielding only starting material. LRMS ESI (+) m/z = 1227.5 (Boc-End A) and 
1234.5 (Boc-End B). Solvents: 2:1 DMF:water, 2:1 MeOH:water, 2:1 DMF:100 mM 
NaAcOH, 2:1 MeOH:100 mM NaAcOH, 2:1 MeCN:water, DMF and MeOH. 
1222-nitroso-toluene/Enduracidin reaction A solution of Boc-End (10 mg, 4 µmol) in 
solvent (500 µL) with 2-nitroso-toluene (5 mg, 40 µmol) in a 4 mL vial was heated at 
70 ºC under Ar for 24 hrs. To a set of reactions was added a CuI catalyst (0.8 mg, 4 
µmol). Catalyzed reactions were run for 24 hrs. at ambient temperature then check by 
MS prior to heating for 24 hrs at 70 ºC. The solvent was then removed under reduced 
pressure. The crude product was dissolved in 70% aqueous MeOH and filtered. HPLC 
and MS analysis indicated no new enduracidin compounds were produced. LRMS ESI 
(+) m/z = 1227.5 (Boc-End A) and 1234.5 (Boc-End B). Solvents: 1:4 DMSO:toluene, 
MeOH,  1:4  DMF:toluene  and  Acetone.  The  solvent  systems  1:4  DMSO:toluene, 
MeOH and 1:4 DMF:toluene were used for the catalyzed series of experiments.
Danishefsky’s diene/Enduracidin reaction A solution of Boc-End (10 mg, 4 µmol) 
in solvent (500 µL, 1:4 DMSO:toluene or 1:4 DMF:toluene) with Danishefsky’s diene 
(8 µL, 40 µmol) in a  4 mL vial was heated at 70 ºC under Ar for 24 hrs. A set of 
reactions were run with TEA (6 eq.) as an additive. To an additional set of reactions 
was added ZnI2 (1.4 mg, 4 µmol) or ZnCl2 (0.6 mg, 4 µmol) as catalysts. Catalyzed 
reactions were  run  for 24  hrs.  at ambient temperature  then  check by MS  prior to 
heating for 24 hrs at 70 ºC. To end the reaction the solvent was removed under reduced 
pressure. The crude product was then dissolved in 70% aqueous MeOH and filtered. 
HPLC and MS analysis indicated no new enduracidin compounds were produced. The 
reactions containing zinc were found to have deprotected Boc-End. LRMS ESI (+) m/z 
= 1177.5 and 1184.5. The  reactions  containing  TEA were found  to  return  starting 
material. LRMS  ESI (+) m/z = 1227.5 (Boc-End A) and 1234.5 (Boc-End B). The 
other solvent systems with  no additive  were found  to degrade the compound. The 
DMSO-toluene reaction was found to produce a new compound which could not be 
identified. LRMS ESI (+) m/z = 1311.5. 
Lipid tail dihydroxylation
123General method  To  a  stirred  solution  of  enduracidin  (30  mg,  13  µmol)  in  70% 
aqueous IPA (500 µL) was added a 2.5% solution of OsO4 in t-BuOH (13 µL, 1 µmol) 
followed by a 50%  solution of NMO in water (10 µL, 38 µmol). The reaction was 
monitored by MS and stopped after 30 min by the addition of saturated Na2SO3 (100 
µL). The solvent was then removed and the crude product dissolved in 70% MeOH, 
syringe filtered (2 µm) and purified by HPLC using  the Polar column method. Six 
products  were  formed.  Three  representative  compounds  were  isolated  and 
characterized.
2,3,4,5-(OH)4-enduracidin A 1H NMR (500 MHz, 2:1 d4-methanol:D2O, 25 ºC) Alkyl 
tail shifts could not be identified; LRMS ESI (+) m/z 1211.5 [M+2H]2+.
2,3-(OH)4-enduracidin B  1H NMR (500 MHz, 2:1 d4-methanol:D2O, 25 ºC) Alkyl 
tail shifts: δ 5.75 (m, 1H, H-5), 5.51 (m, 1H, H-4), 4.29 (m 1H, H-3), 2.02 (m, 2H, 
H-6); LRMS ESI (+) m/z 1201.5 [M+2H]2+.
4,5-(OH)4-enduracidin A: 1H NMR (500 MHz, 2:1 d4-methanol:D2O, 25 ºC) Alkyl 
tail shifts: δ 6.14 (m, 1H, H-2), 5.11 (m, 1H, H-3), 3.53 (m 1H, H-4), 1.51 (m, 1H, 
H-5); LRMS ESI (+) m/z 1194.5 [M+2H]2+.
Enduracidin nitration
Sodium nitrite general method: To a stirred solution of Fmoc-End (6 mg, 2 µmol) in 
AcOH (1 mL) under Ar was added NaNO2 (1.5 mg, 16 µmol). The reaction was stirred 
for 3 hrs. The solvent was removed under reduced pressure and the crude product was 
dissolved in 70% MeOH and syringe filtered. The reaction was analyzed by HPLC 
and MS indicating the degradation of the compound. Solvent conditions were altered 
to  1:2 water:AcOH to aid in solubility yielding  on degraded product. The reaction 
conditions were altered with the water-AcOH reactions cooling the reaction in an ice 
bath. Reaction times were reduced to 30 minutes in an attempt to prevent degradation. 
All reaction conditions resulted in product degradation.
124Potassium nitrate general method: To  a  stirred  solution  of  Fmoc-End  (6  mg,  2 
µmol) in TFA (1 mL) under Ar was added KNO3 (12 mg, 0.12 mmol). The reaction 
was stirred for 2 hrs. The solvent was removed under reduced pressure and the crude 
product was dissolved in 70% MeOH and syringe filtered. The reaction was analyzed 
by HPLC (Polar column isolation method) and  MS  indicating  that no reaction had 
occurred. LRMS  ESI (+) m/z = 1288.5 (Fmoc-End A) and  1295.5  (Fmoc-End  B). 
Solvent conditions were altered to 1:2 water:TFA and 100% AcOH to aid in solubility. 
The altered reaction conditions resulted in only starting material.
Tetranitromethane general method: To a solution of Fmoc-End (10 mg, 4 µmol) 
was dissolved in 2 mL of (1:1) MeOH:10 mM ammoniumacetate pH 7 and stirred at 
room  temperature.  Tetranitromethane  (17 mg, 85  µmol)  in  2.7  mL  of MeOH was 
added slowly over 30 min and stirred for 5 h. The reaction was halted by the addition 
of AcOH (0.5 mL) and the solvent was removed under reduced pressure. The crude 
product  was  dissolved  in  70%  aqueous  MeOH and  analyzed  by HPLC  (Kinetex 
analysis method) and MS. Only starting material was observed. HPLC, retention time 
5.7 and 6.0 min; LRMS ESI (+) m/z = 1288.5 (Fmoc-End A) and 1295.5 (Fmoc-End 
B). 
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132CHAPTER FIVE
GENERAL CONCLUSIONS
Neal GoebelBiosynthetic Studies
 T h e   u n d e r s t a n d i n g   o f   t h e   b i o s y n t h e t i c   p a t h w a y s   i n v o l v e d   i n   p r o d u c i n g  
enduracidin  precursors,  and  tailoring  enduracidin  lays  a  foundation  for  the 
modification  of enduracidin through  genetic  manipulation. Additionally, large-scale 
production of enduracididine through biochemical methods would aid in research into 
new  mannopeptimycin  analogs. Presently much  of  the  enduracididine  biosynthetic 
pathway remains unknown. The bioassay results, while not clearly elucidating enzyme 
function,  indicated  that  4-hydroxyarginine  (4-OH-Arg)  or  a  variant  serves  as  an 
intermediate in the pathway. Our collaborative work has shown that EndR/MppR is 
responsible  for  the  cyclization  reaction  forming  the  aminoimidazoline  ring.  It  is 
evident from the complementation experiments that EndQ can act as a transaminase 
using 4-OH Arg and 2-ketoenduracididine as substrates. EndP and EndQ are predicted 
to function as transaminases. The timing of the introduction of the 4-hydroxyl group 
on arginine  is still unknown. Because the biosyntheses of related compounds,  like 
capreomycidine, rely on monooxygenases for similar reactions it seems likely that the 
S.  fungicidicus a n d  Amycolatopsis  hygroscopicus g e n o m e s  m a y  c o n t a i n  a  
monooxygenase for the biosynthesis of 4-OH Arg. Additional research sequencing the 
genome,  bioinformatic  analysis  and  genetic  disruption experiments should  provide 
further  insight  into  the  production  of  4-OH  Arg.  The  continued  work  of  our 
collaborator  (Dr.  Nicholas  Silvaggi,  University of  Wisconsin-Milwaukee)  into  the 
structure and function of MppP and MppQ should provide insight into each enzyme’s 
function in enduracididine biosynthesis.
  The biosynthetic work on the lipid tail provides limited information on the roles 
of  each  enzyme  proposed  to  introduce  the  diene.  Bioinformatic  data  and  the 
production of H4-enduracidin in orf45 disruptants suggest that Orf45 is responsible for 
the formation of the lipid-CoA thioester and the introduction of the C2 double bond. 
134The proposed function of Orf44 and Orf39 are the isomerization of the C2 alkene and 
introduction of the C4 olefin. The clarification of each individual enzyme’s role will 
require a more direct approach and will likely involve purified protein assays, NMR or 
crystallization for the determination of the structure of the proteins bound to possible 
substrates.  The  possibility  of  protein-protein  interactions  and  the  potential  that a 
mutant-produced lipid tail with alternate stereochemistry is not being incorporated into 
enduracidin due to enzyme stereoselectivity prevents the mutagenic approach from 
revealing the exact details of the biosynthetic pathway.
  The  biosynthetic  function  of  the  halogenase,  Orf30,  was  probed  during  the 
incorporation  experiments  using  2-F  and  3-F-Hpg.  The  production  of  deschloro 
enduracidin by S. fungicidicus supplemented with 3-F-Hpg indicates that Orf30 may 
be inhibited by 3-F-Hpg. This fact appears to be confirmed as both the  mono and 
deschloro species of  3’-F6-enduracidin  are  produced.  Interestingly, the  presence  of 
fluorine  in  the  2’  position  of  Hpg-13  also  inhibited  halogenation,  yielding  the 
monochloro species. The halogenation appears to occur at the 5’ position according to 
NMR analysis. The production of dichloro-3’-F6-enduracidin and the 19F-NMR data of 
dichloro-2’-F6-enduracidin suggest that the halogenase  can act on an alternate Hpg 
residue. The confirmation of this data will hopefully be resolved by MS/MS analysis, 
which  has to  this point failed. The  production  of more  compound is  possible and 
would allow the determination to be made by NMR spectroscopy. 
Semisynthetic Studies
  The  semisynthetic  studies  with  enduracidin  have  indicated  that  few  of  the 
modification  routes  attempted  are  viable.  Enduracidin’s  apparent  sensitivity  to 
oxidation,  as  observed  in  the  ozonolysis  and  nitration  reactions,  limits  the 
semisynthetic methods possible. Interestingly, hydroxylation of the enduracidin lipid 
diene  proved  to  be  a  feasible  approach.  The  production  of  three  dihydroxylation 
135products  using  OsO4  and  NMO  provided  valuable  information  concerning  the 
introduction of polar groups on the lipid tail. C2 and C3 dihydroxylated enduracidin 
proved to have with the best bioactivity though it was significantly reduced compared 
to the parent antibiotic. The introduction of more hydroxyl groups, further down the 
lipid tail, decreased bioactivity further, providing  useful data for minimal length of 
alternate lipid tails. Exploration of modifications to the dihydroxyl groups should be 
approached next. The  reduction of the  lipid tail double bonds appears to have little 
effect on the bioactivity. The structures did prove useful in the analysis of the lipid tail 
biosynthesis.  Future  work  in  this  area  should  involve  the  use  of  an  enzymatic 
deacylation reaction and subsequent alkylation to access new enduracidin analogs. 
  The  use  of  the  lipid  tail  diene  in  a  variety  of  Diels-Alder  reactions  was 
unsuccessful. The natural configuration appears to prevent the proper alignment for 
the diene to react in a [4+2] reaction. Use of a lipid tail olefin as a dienophile similarly 
proved unsuccessful. Using Danishefsky’s diene, one product was observed by MS but 
could not be isolated and did not correspond to a predicted product.
Mutasynthetic Modification of Enduracidin
  By utilizing the data known about hydroxyphenylglycine (Hpg) biosynthesis the 
incorporation of fluorine, through F-Hpg, into enduracidin was achieved. Two F-Hpg 
isomers (2-F-Hpg  and  3-F-Hpg)  were  found  to  incorporate  into  enduracidin.  The 
incorporation of a difluoro-Hpg or nitro-Hpg was unsuccessful. The minimal loss of 
bioactivity for both 2’-F6 and 3’-F6-enduracidin indicated that the  Hpg  residues are 
viable targets for modification. Low production of 2’-F6-enduracidin limits its viability 
for larger scale production. Presently the specificity of wild-type biosynthetic enzymes 
limit the number of compounds capable of being produced. Future work to modify the 
adenylation  domains  may increase  production of  F6-enduracidin  and allow  for  the 
incorporation of nitro-Hpg and other Hpg variants. Further analysis of this method for 
136modifying the physical properties of enduracidin is needed. While lab-scale methods 
are  inefficient at producing  the large quantities of compound, larger scale  cultures 
using  a  bioreactor  could  provide  sufficient  compound  for  the  evaluation  of  the 
physical properties of each of the F6-enduracidins. These general methods should be 
applicable to other organisms producing Hpg-containing natural products. 
Potential of Enduracidin
  Though  failing  to  be  developed for  clinical  use  during  its initial  evaluation, 
enduracidin still  holds high potential  for use as a  clinical  antibiotic. The continued 
battle against drug resistant bacterial strains necessitates the development of new and 
potent antibiotics. The work presented here has demonstrated a preliminary proof of 
concept for the  mutasynthetic  modification of  enduracidin and some  semisynthetic 
modifications.  Further  exploration  of  new analogs  and  their  production  is  needed 
before  extensive  biological  evaluations  can  begin.  The  methods  of  production, 
particularly by mutasynthesis, can be refined and improved. Additionally, the use of 
enduracidin  and  related  peptides  as  feed  additives  needs  to  be  reexamined.  The 
potential for developing resistance remains and minimization of antibiotic use at sub-
therapeutic levels is needed in order to preserve human clinical efficacy. The study of 
enduracidin, its mechanism of action and biosynthesis demonstrates its rarity as an 
antibiotic.
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